Insured Profile Report – Management Liability Focus ......Johnson & Johnson 4/18/1982 $170.40...

Insured Profile Report – Management Liability Focus

Johnson & Johnson_________________________________________________________________________

Company Profile

Location 1 Johnson and Johnson PlzNew Brunswick, NJwww.jnj.com

Company Type Public

Formerly Known As N/A

SIC Code 2834

SIC Code Description Pharmaceutical Preparations

Established 1955

Sales (in millions) $65,030.00

Employees 117,900

Total OSHA Violations 18

OSHA is an arm of the Department of Labor that conducts inspections of company facilities with the goal of preventing work-related injuries, illnesses and deaths. Worksites that do not meet health and/or safety standards at the time of inspection may receive an OSHA violation.

Total FDA NDC Drugs 177

The total number of FDA Drugs filed in the FDA NDC Drug Database.

Credit Details

Overall Credit Risk High Risk

Number of Legal Derogatory Items

84

Liability Amount $322,285.00

Experian Intelliscore 2.57

Experian Intelliscore Percentile 2.00 % of companies score lower and have higher credit risk

Experian Commercial IntelliscoreSM is an all-industry commercial model using business information to predict business risk. Its predictiveness is among the best on the market todayThe objective of the Commercial Intelliscore Model is to predict seriously derogatory payment behavior. Possible score range from 0 to 100, where 0 is high risk and 100 is low risk-Liability Amount is the total dollar amount of debtor’s legal liability,including accounts in collection, tax liens,judgments and/or bankruptcies-The Number of Legal Derogatory items are the sum of Tax-Lien Count, Bankruptcy,Judgment, Collection-Counter and UCC Derog

Litigation & Losses

Business Description

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's healthcare fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment includes products in the therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology, Inc. with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock.

For more information contact your Advisen rep at +1.212.897.4800, email [email protected], or visit www.advisen.com

1

http://www.advisen.com/







Top Company Management Liability Cases by Settlement Amount

Company Acc/Filing Date

Amount(in millions)

Category Subtype Docket Number Court State

Johnson & Johnson 1/1/2004 $1,000.00 Business & Trade Practices

Sales Practices Unknown Pennsylvania

In January 2004, Janssen Pharmaceuticals, Inc. (JPI) received a subpoena from the Office of the Inspector General of the United States Office of Personnel Management seeking documents concerning sales and marketing of, any and all payments to physicians in connection with sales and marketing of RISPERDAL from 1997 to 2002. Documents subsequent to 2002 have also been requested by the Department of Justice. An additional subpoena seeking information about marketing of, and adverse reactions to, RISPERDAL was received from the United States Attorney's Office for the Eastern District of Pennsylvania in November 2005. Numerous subpoenas seeking testimony from various witnesses before a grand jury were also received. JPI cooperated in responding to these requests for documents and witnesses. The United States Department of Justice and the United States Attorney's Office for the Eastern District of Pennsylvania (the Government) are continuing to actively pursue both criminal and civil actions. In February 2010, the Government served Civil Investigative Demands seeking additional information relating to sales and marketing of RISPERDAL and sales and marketing of INVEGA . The focus of these matters is the alleged promotion of RISPERDAL and INVEGA for off-label uses. In an article dated January 5, 2012, the parent company of JPI, Johnson & Johnson, is said to pay more than $1 billion to the Government and most states to resolve a civil investigation into marketing of the antipsychotic Risperdal. However, when the final settlement will be announced isn't clear yet.

Ortho-Mcneil-Janssen Pharmaceuticals, Inc.

1/1/2007 $327.07 Business & Trade Practices

Marketing Practices 07-CP-42-1438 South Carolina

On June 3, 2011, a South Carolina judge ordered Ortho-McNeil-Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson to pay $327,073,700 to the state in its civil penalties for misleading the doctors about the safety and effectiveness of antipsychotic Risperdal. The state jury ruled that a J&J communication sent to doctors violated the state's unfair trade practices act by engaging in unfair or deceptive acts. The accusation was made specifically with regards to a dear doctor letter from November 2003, sent to over 7,000 physicians, and the drug label on Risperdal (risperidone) which were allegedly misleading about its safety and effectiveness. The jury also found that the violations of the South Carolina Unfair Trade Practices Act were willful, that the Risperdal label or package insert was unfair or deceptive and that the defendant willfully violated the Unfair Trade Practices Act. The penalty was to be determined by Judge Roger L. Couch. For the deceptive label, Judge Couch penalized Ortho-McNeil-Janssen $300 for each of the 509,499 sample boxes of Risperdal distributed in South Carolina from 1999 until April 2007, for a total of $152,849,700. Judge Couch said there clearly were other occasions when Ortho-McNeil-Janssen distributed deceptive labels, including publication in the Physician's Desk Reference and the defendant's website, but to find those violations would require speculation. He said the number of Risperdal samples given away in South Carolina is known. For the deceptive "dear doctor" letters, Judge Couch found that in South Carolina there were 7,184 letters mailed and 36,372 sales calls to doctors in which letters were distributed, for a total of 43,566 publications. He assessed a penalty of $4,000 for each deceptive "dear doctor" letter, for a total of $174,224,000.

Janssen Pharmaceuticals, Inc.


Marketing Practices 2007-CP-42-1438 South Carolina

On June 3, 2011, a Johnson & Johnson (JNJ) unit was ordered by a South Carolina judge to pay more than $327 million in penalties for deceptively marketing the antipsychotic drug Risperdal as safer as and better than competing medicines. J&J's Ortho McNeil Janssen Pharmaceuticals unit repeatedly violated the state's consumer protection laws by sending a 2003 letter to doctors touting Risperdal as superior to rival drugs and including deceptive information in the product's warning label, Judge Roger Couch in Spartanburg, South Carolina, concluded. The drugmaker's executives allowed the profit at all costs mentality to cloud their judgment in connection with the drug's marketing campaign and its labeling, Couch said in his 17 page ruling. Janssen official said yesterday they'll appeal Couch's order and maintained the company fully disclosed Risperdal's health risks and properly marketed the antipsychotic medicine. South Carolina's lawyers, who originally sued the J&J unit in 2007 for making misleading claims about Risperdal, sought billions of dollars in penalties over the targeted marketing and labeling material.

Johnson & Johnson 1/1/2004 $257.68 Business & Trade Practices

Marketing Practices 04-C-3967-D Louisiana

Maker Misrepresented Drug's Link to Diabetes, Govt. Claimed: The plaintiff is the state of Louisiana. Since 1994, Janssen Pharmaceutica, Inc. and Johnson & Johnson's drug Risperdal was marketed to treat schizophrenia. The State Attorney General's Office sued Janssen Pharmaceutica and its parent company, Johnson & Johnson, alleging violations of various state statutes including the Medical Assistance Programs Integrity Law. Plaintiffs' counsel claimed that in November 2003, Janssen Pharmaceutica sent a false and misleading letter to various health care providers misrepresenting and minimizing Risperdal's link to diabetes in order to obtain funds from the state Medicaid Program. Plaintiff's counsel alleged that Johnson & Johnson and Janssen sent "Dear Doctor" letters to more than 7,500 Louisiana health care providers stating that Risperdal was safer than other competing brand name antipsychotic drugs. The defendants continued to disseminate these false and misleading claims in more than 27,000 marketing calls to various health care providers, according to plaintiff's counsel. The Food and Drug Administration had previously sent a letter to Janssen Pharmaceutica, Inc. and Johnson & Johnson regarding the false and misleading claims that minimized the risk of diabetes associated with Risperdal and overstated the drug's supremacy to rival medicines, according to plaintiffs' counsel. Defense counsel argued that hyperglycemia-related adverse events had infrequently been reported in patients receiving Risperdal. A body of peer-reviewed research suggested that Risperdal was not associated with an increased risk of diabetes when compared to untreated patients or patients with conventional antipsychotics. Plaintiffs' counsel noted that in a January 8, 2004, e-mail, Janssen executives acknowledged that they did not have the "very compelling data" required by the FDA to reverse the FDA's class-wide labeling mandate regarding the increased risk of diabetes by all atypical anti-psychotics. The state sought to recover actual damages sustained as a result of the defendants' violations, a civil monetary penalty for each violation and interest in addition to costs, expenses and fees. The jury found that there were 35,542 violations of the state's Medical Assistance Programs Integrity Law. The jury also found that Janssen Pharmaceutica was 90 percent liable while Johnson & Johnson was 10 percent liable. The jury awarded $7,250 for each of the violations for an award total of $257,679,500.

Johnson & Johnson 4/18/1982 $170.40 Management & Strategy

Anti-trust Unknown New Jersey

On April 19, 1982, a federal judge upheld a jury's decision that Johnson & Johnson must pay three men $170.4 million because it suppressed their painkilling device from the market to protect sales of its own pills such as Tylenol. The damages were awarded to three Minnesota men who invented a "transcutaneous electronic nerve stimulator" or TENS, a battery-powered device that blocks pain and helps heal surgical incisions through small electrodes attached to the skin. The jury ruled, in effect, that Johnson & Johnson bought TENS for $1.3 million plus a promise to share in $7 million of future profits. Then, the jury found Johnson & Johnson suppressed it. The judge said that the device could have been used by "countless individuals" without the side effects and addiction that can accompany painkilling pills. The judge said that Johnson & Johnson deliberately suppressed the device to sell more Tylenol, a painkiller that does not contain aspirin, and the drug Zomax. And that Johnson & Johnson is still selling addictive, debilitating, and to some patients, drugs which in the long run poison them, and it continues to suppress TENS therapy which would prevent such poisoning and permit patients to live in a pain-free existence with no side effects. The judge said that the evidence "fully justifies" the jury award against the pharmaceutical giant. This is believed to be the largest award ever to private parties in an antitrust action.

Janssen Pharmaceuticals, Inc.


Billing Fraud D-1-GV-04-001288 Texas

In 2004, the State of Texas and Allen Jones (collectively, plaintiffs) filed a whistleblower lawsuit against Janssen LP, Janssen Pharmaceutical, Inc., Ortho-McNeil Pharmaceutical, Inc., McNeil Consumer & Specialty Pharmaceuticals, Janssen-Ortho, LLC and Johnson & Johnson (collectively, defendants) in the Travis County District Court. The lawsuit claimed that starting from 1994 to 2008 defendants misrepresented the risks and approved used of Risperdal, including use in children. Risperdal is one of three atypical antipsychotic drugs that were used to treat schizophrenia. Plaintiffs, including individuals and third-party payers such as states and health insurers, alleged that the defendants failed to warn that the drugs caused excessive weight gain, high blood sugar and diabetes. Also, the lawsuit stated that the state was defrauded by having to pay for Medicaid prescriptions for Risperdal for off-label uses, costing the state millions. On


2








January 19, 2012, both parties reached a settlement agreement. Under the terms of the settlement, defendants will pay $158 million in full resolution of all claims in Texas.


Foreign Corrupt Practices Act (DoJ)

Unknown New Jersey

On April 11, 2011, Johnson & Johnson will pay $78 million to settle U.S. and UK charges that it paid bribes and kickbacks to win business overseas, the first big drug company to settle since the Obama administration began its scrutiny of the industry more than a year ago. Johnson & Johnson agreed to pay a $21.4 million fine to settle Justice Department criminal charges and pay more than $48.6 million in disgorgement and interest to settle allegations by the Securities and Exchange Commission, the agencies said on Friday. The allegations date back to 1998 and involved sham contracts, bribes and kickbacks paid by J&J units to officials and doctors in Greece, Iraq, Poland and Romania to help earn millions of dollars in profits, according to authorities. The New Jersey-based pharmaceutical giant also settled a similar complaint with the United Kingdom Serious Fraud Office for conduct by its DePuy Inc subsidiary, agreeing to pay some $7.9 million plus prosecution costs. The U.S. Justice Department announced in November 2009 that it would focus on prosecuting those in the pharmaceutical industry who try to bribe foreign officials for preferential treatment of their products, leading to a wide-ranging probe. U.S. authorities praised the cooperation by the company, its remedial efforts and said that it helped identify improper practices in the industry. The criminal fine was reduced in light of the company's cooperation.

Johnson & Johnson 6/14/1984 $60.00 Management & Strategy

Anti-trust Undisclosed Florida

On May 22, 2011, the consumers who purchased contact lenses in the last 14 years would be eligible to receive cash rebates on future lens purchases and eye exams under a proposed settlement with Johnson & Johnson Vision Care, Inc. Johnson & Johnson was the last non-settling defendant in an antitrust action brought by California, 31 other states, and a private consumer class against contact lens manufacturers and the American Optometric Association. Settlements with the American Optometric Association and 13 individual optometrist defendants also received preliminary approval today. "This has been long, hard-fought litigation for consumers with California's active involvement," Attorney General Lockyer said. "The settlement provides tangible benefits to consumers who use and purchase replacement contact lenses." Californians who bought replacement contact lenses from Johnson & Johnson, Bausch & Lomb, or CIBA Vision at any time since January 1, 1988, are eligible to receive rebates under the proposed settlement. Acuvue , SeeQuence , Focus , and NuVues are among the brands sold by these manufacturers. More than 10 percent of Americans wear contact lenses. Because Johnson & Johnson, Bausch & Lomb and CIBA make the most widely sold brands, most of these consumers are eligible for benefits under the settlement. Eligible consumers may receive benefits both under the proposed settlement with Johnson & Johnson and under a proposed settlement reached with Bausch & Lomb in January. California and the other plaintiffs moved for preliminary court approval of the Johnson & Johnson settlement agreement. The Bausch & Lomb settlement received preliminarily court approval earlier. The settled lawsuits alleged that retail prices of disposable contact lenses were too high because Johnson & Johnson and the other defendant manufacturers agreed with Optometric Association representatives, in violation of the antitrust laws, that their lenses would be available only from eye care professionals (optometrists, ophthalmologists and opticians), retail optical stores or certain mass merchandisers. Plaintiffs alleged that because of this illegal agreement consumers had more difficulty buying replacement lenses through the mail or from pharmacies. Johnson and Johnson denies participating in the alleged agreement. All the defendant manufacturers claimed their refusals to sell to outlets such as mail order and pharmacies were not the result of an illegal agreement. All defendants also deny that their actions cause retail prices of replacement lenses to be above competitive levels. Under the proposed settlement, Johnson & Johnson guaranteed to distribute at least $30 million of rebates to consumers. Bausch & Lomb also guaranteed to distribute at least $9.5 million of rebates and coupons. If less than the guaranteed amounts are distributed, each manufacturer agreed to pay into a settlement fund the difference between its guarantee and the amount actually distributed. The consumer benefits package will include $50 off the purchase of four six packs of disposable lenses and $25 off the cost of an eye examination by an eye care professional plus an additional $25 off a future purchase of four or more lens six packs. Four six packs of lenses can cost consumers anywhere from about $75 to $100 or more. In addition to offering consumers the benefits package, Johnson & Johnson agreed to pay $25 million in cash into a settlement fund. In prior settlements in the litigation, Bausch & Lomb agreed to pay $8 million in cash and CIBA agreed to pay $5 million. The AOA agreed to pay $750,000 and 13 individuals agreed to pay $8,000 each. Attorneys fees and litigation expenses will be paid out of all these settlement funds and the defendants will not be making additional payments to cover the attorneys fees or other litigation expenses. For consumers who formerly wore Johnson & Johnson contact lenses but no longer do so, Johnson & Johnson agreed to pay up to $5 million in cash or coupons. Those consumers will have the choice of $35 in cash or $50 in coupons upon filing of an appropriate claim form including proof of a valid prescription for Johnson & Johnson lenses, a receipt showing a purchase after January 1, 1988 or a statement from a patient's eye care practitioner that he or she purchased Johnson & Johnson disposable lenses. A full description of the criteria for payment is contained the notice and claim form. Plaintiffs will seek to establish a similar fund for people who have stopped wearing B&L and CIBA lenses. Both Johnson & Johnson and Bausch & Lomb agreed to change their distribution practices. The applicable provision in the settlement with Johnson & Johnson provides: Injunctive Relief: (a) Johnson & Johnson will sell and distribute its replacement contact lenses to alternative channels of distribution (as defined in this Settlement Agreement) for a period of five (5) years from the date this Settlement Agreement becomes final under paragraph 12 hereof. (b) Subject to subparagraph (a) above, Johnson & Johnson will sell to alternative channels of distribution in a commercially reasonable and non-discriminatory manner, provided that any such alternative channel of distribution, like any other authorized account, will sell contact lenses only to consumers based upon a valid prescription and in compliance with all federal and state laws and regulations regarding the sale or dispensing of contact lenses, and agrees not to substitute diagnostic lenses for a revenue-producing product. Bausch & Lomb similarly agreed to sell to alternative channels of distribution in a commercially reasonable and non-discriminatory manner, provided that the alternative channel accounts meet the same terms and conditions of all other accounts. Under its settlement, the American Optometric Association agreed not to ask or encourage a contact lens manufacturer to refuse to sell contact lenses to any channel of trade; not to encourage or support a refusal by optometrists, in writing prescriptions, to favor any manufacturer because its lenses are sold by outlets other than eye care professionals; not to claim, without scientific proof, that there is a link between eye health problems and the channel of trade from which contact lenses are purchased; not to oppose consumers getting their contact lens prescriptions on request, except on valid medical grounds and as consistent with state law; and to publish a letter from the AOA's president in the AOA News setting forth these agreements. Trial of the case against Johnson & Johnson and the AOA began March 19, 2001, in the federal district court in Jacksonville, Florida.


Fraudulent Trade Practices

212-MD-2004 Pennsylvania

State, Drug Dispenser Disputed Reimbursement Rates: The Commonwealth of Pennsylvania, through its Medicaid and PACE programs, reimburses pharmacies and other health care providers in the state that purchase wholesale-priced drugs from pharmaceutical companies such as Johnson & Johnson, of New Brunswick, N.J. The state claimed that Johnson & Johnson overstated the average wholesale prices (AWPs) of the drugs it purchased, resulting in higher reimbursements to providers. The state sued Johnson & Johnson, claiming violations of the state's Unfair Trade Practices and Consumer Protection Law, as well as unjust enrichment, misrepresentation, fraud and civil conspiracy. The matter proceeded to a bench trial. Counsel for the state claimed that Johnson & Johnson used the excessive reimbursements from the state to market its high profits to its various drug dispensers. The complaint offered the example of the defendant's product Remicade, which was allegedly marketed based on the notion that physicians could profit from dispensing the drugs, since the price at which physicians would purchase them was lower than the price at which they would be reimbursed by the state. The complaint further alleged that Johnson & Johnson engaged in similar practices when marketing prescription drugs to pharmacists. The state claimed that the defendant attempted to cover up the real AWPs by providing rebates, discounts and other financial incentives to pharmacists, and asking physicians to keep those incentives confidential. The state claimed that the defendant annually raised the AWPs of its drugs without reflecting these discounts. Johnson & Johnson, in its motion for compulsory non-suit, argued that the state knew the AWPs did not reflect any drugs' actual acquisition costs, but chose to rely on the pricing anyway. The defendant further argued that the state intended its reimbursement rates to be higher than rates in other states, to ensure that drug dispensers would make a profit on the cost of ingredients, thus ensuring dispensers' future participation in the Medicaid and PACE programs and that beneficiaries would have access to care. The defendant also argued that the state's claims presented a non-justifiable political question, because the Pennsylvania legislature deliberately selected the Medicaid and PACE reimbursement rates, and because the state sought damages based on the rates the programs would have paid if they had relied on lower reimbursement rates, implemented by other payors and states that Pennsylvania chose not to adopt. The state sought damages in excess of $100 million, based upon four different damage methodologies put forth by its expert economists. The defendant's expert disputed the plaintiff's damage estimates, but conceded certain minimum damages, if liability was proven. On June 14, 2010, the judge rule in favor of Johnson & Johnson with regard to the state's claims of unjust enrichment, misrepresentation, fraud and civil conspiracy. On December 7, 2010, the judge ruled in favor of the plaintiff's claim under the Unfair Trade Practice and Consumer Protection Law, ordering the defendant to reimburse the state government $45,283,562 and pay civil penalties in the amount of $6,567,000, for a total award of $51,850,562. The judge also barred the defendant from quoting increased AWPs for its drugs to state programs, without also reporting current


3








acquisition costs, such as average manufacturers' prices or average sales prices. Post-trial motions and appeals are anticipated.

Johnson & Johnson 4/8/2011 $48.67 Securities Foreign Corrupt Practices Act (SEC)

1:11-CV-00686 District of Columbia

Litigation Release No. 21922 / April 8, 2011 Accounting and Auditing Enforcement Release No. 3261 / April 8, 2011 Securities and Exchange Commission v. Johnson & Johnson, Civil Action No. 1: 11-CV-00686 (D.D.C.) (E.F.H.) (filed April 8, 2011) JOHNSON & JOHNSON TO PAY MORE THAN $70 MILLION IN SETTLED FCPA ENFORCEMENT ACTION The Securities and Exchange Commission announced a settlement with Johnson and Johnson ("J&J") to resolve SEC charges that the New Brunswick, NJ-based global pharmaceutical, consumer product, and medical device company violated the Foreign Corrupt Practices Act (FCPA) by bribing public doctors in several European countries and paying kickbacks to Iraq to illegally obtain business. The SEC alleges that, since at least 1998, J&J's subsidiaries paid bribes to public doctors in Greece who selected J&J surgical implants, paid bribes to public doctors and hospital administrators in Poland who awarded tenders to J&J, and paid bribes to public doctors in Romania to prescribe J&J pharmaceutical products. J&J also paid kickbacks to Iraq in order to obtain contracts under the United Nations Oil for Food Program ("Program"). J&J has agreed to pay more than $48.6 million in disgorgement and prejudgment interest to settle the SEC's charges and to pay a $21.4 million fine to the U.S. Department of Justice to settle criminal charges. A resolution of a related investigation by the United Kingdom Serious Fraud Office is anticipated. The SEC's complaint alleges that J&J subsidiaries, employees, and agents paid bribes to public doctors and administrators in Greece, Poland, and Romania. Doctors who ordered or prescribed J&J products were rewarded in a variety of ways, including cash and inappropriate travel. A variety of schemes were used to carry-out the bribery, including the use of slush funds, sham civil contracts with doctors, and off-shore companies in the Isle of Man. A J&J executive was involved in the Greek conduct, and MD&D Poland executives running three business lines oversaw the creation of sham contracts, travel documents, and the creation of slush funds in Poland. The SEC's complaint also alleges that J&J's agent paid secret kickbacks to Iraq to obtain nineteen Oil for Food contracts. Without admitting or denying the SEC's allegations, J&J has consented to the entry of a court order permanently enjoining it from future violations of Sections 30A, 13(b)(2)(A), and 13(b)(2)(B) of the Securities Exchange Act of 1934; ordering it to pay $38,227,826 in disgorgement and $10,438,490 in prejudgment interest; and ordering it to comply with certain undertakings regarding its FCPA compliance program. J&J voluntarily disclosed some of the violations by its employees, and conducted a thorough internal investigation to determine the scope of the bribery and other violations, including proactive investigations in more than a dozen countries by both its internal auditors and outside counsel. J&J's internal investigation and its ongoing compliance programs were essential in gathering facts regarding the full extent of J&J's FCPA violations. Kelly G. Kilroy and Tracy L. Price of the Enforcement Division's FCPA Unit and Brent S. Mitchell and Reid A. Muoio conducted the SEC's investigation. The SEC acknowledges the assistance of the U.S. Department of Justice, Fraud Section; the Federal Bureau of Investigation; the Serious Fraud Office in the United Kingdom; and 5th Investigation Department of the Regional Prosecutor's Office in Radom, Poland. The SEC's investigation is continuing.


Sales Practices 04-CV-11886-MLW Massachusetts

On December 2, 2003, Dr. Gary R. Spivack filed a qui tam action in the United States District Court for the Eastern District of New York against American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson alleging False Claims Act that they illegally promoted Topamax and caused false claims to be submitted to government health care programs for a variety of psychiatric uses that were not medically accepted indications and therefore not covered by those programs. On August 12, 2004, the action was transferred to the District Court of Massachusetts. On April 29, 2010, the United States Department of Justice announced that the pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., have agreed to pay more $75.37 million to resolve the civil allegations. The federal share of the civil settlement is $50,688,483.52, and the state Medicaid share of the civil settlement is $24,681,516.48. Also as part of the settlement, Ortho-McNeil-Janssen Pharmaceuticals has agreed to enter into an expansive corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services. That agreement provides for procedures and reviews to be put in place to avoid and promptly detect conduct similar to that which gave rise to this matter. The civil settlement resolves two lawsuits filed under the qui tam, or whistleblower, provisions of the False Claims Act, which allow private citizens with knowledge of fraud to bring civil actions behalf of the United States and share in any recovery. The two cases, both filed in the District of Massachusetts are United States ex rel. Maher, et al. v. Ortho-McNeil Pharmaceutical, Civil Action No. 03-11445-WGY, and United States ex rel. Spivack v. Johnson & Johnson and Ortho-McNeil Pharmaceutical, Inc., Civil Action No. 04-11886-WGY. As part of today's resolution, the whistleblowers will receive payments totaling more than $9 million from the federal share of the civil recovery.

Ortho-Mcneil-Janssen Pharmaceuticals, Inc.


Sales Practices 03-11445-WGY Massachusetts

On August 5, 2003, Angela Maher and Anastasia Savka-Klovski (Maher Realtors) filed a qui tam action in the United States District Court of Massachusetts against the American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnso alleging criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax. On April 29, 2010, the United States Department of Justice announced that the American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., have agreed to pay more than $81 million to resolve the suit. According to the agreement reached with the government, Ortho-McNeil Pharmaceutical LLC has agreed to plead guilty to a misdemeanor and pay a $6.14 million criminal fine for the misbranding of Topamax in violation of the Food, Drug and Cosmetic Act. The Food and Drug Administration (FDA) approved Topamax as an anti-epileptic drug, for the treatment of partial onset seizures, but not for any psychiatric use. Once a pharmaceutical is approved by the FDA, a manufacturer may not market or promote it for any use not specified in its new drug application. The unauthorized uses are also known as unapproved or off-label uses. The government alleged that Ortho-McNeil Pharmaceutical promoted the sale of Topamax for off-label psychiatric uses through a practice known as the "Doctor-for-a-Day" program. Using this program, Ortho-McNeil hired outside physicians to join sales representatives in their visits to the offices of health care providers and to speak at meetings and dinners about prescribing Topamax for unapproved uses and doses. Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals have admitted that they promoted Topamax between 2001 and 2003 for uses that were not approved by the FDA. Also as part of the settlement, Ortho-McNeil-Janssen Pharmaceuticals has agreed to enter into an expansive corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services. That agreement provides for procedures and reviews to be put in place to avoid and promptly detect conduct similar to that which gave rise to this matter.

Johnson & Johnson 4/8/2011 $21.40 Securities Foreign Corrupt Practices Act (SEC)

Undisclosed District of Columbia

On April 8, 2011, Johnson & Johnson (J&J) has agreed to pay a $21.4 million criminal penalty as part of a deferred prosecution agreement with the Department of Justice to resolve improper payments by J&J subsidiaries to government officials in Greece, Poland and Romania in violation of the Foreign Corrupt Practices Act (FCPA. The agreement also resolves kickbacks paid to the former government of Iraq under the United Nations Oil for Food Program. Johnson & Johnson has admitted that its subsidiaries, employees and agents paid bribes to publicly-employed health care providers in Greece, Poland and Romania, and that kickbacks were paid on behalf of Johnson & Johnson subsidiary companies to the former government of Iraq under the United Nations Oil for Food program. Johnson & Johnson, however, has also cooperated extensively with the government and, as a result, has played an important role in identifying improper practices in the life sciences industry. As today's agreement reflects, we are committed to holding corporations accountable for bribing foreign officials while, at the same time, giving meaningful credit to companies that self-report and cooperate with our investigations. According to the agreement, J&J has acknowledged responsibility for the actions of its subsidiaries, employees and agents who made various improper payments to publicly-employed health care providers in Greece, Poland and Romania in order to induce the purchase of medical devices and pharmaceuticals manufactured by J&J subsidiaries. J&J also acknowledged that kickbacks were paid on behalf of J&J subsidiary companies to the former government of Iraq under the United Nations Oil for Food Program in order to secure contracts to provide humanitarian supplies. A criminal information, filed in U.S. District Court in the District of Columbia in connection with the deferred prosecution agreement, charges J&J subsidiary DePuy Inc. with conspiracy and violations of the FCPA in connection with the payments to public physicians in Greece. The agreement recognizes J&J's timely voluntary disclosure, and thorough and wide-reaching self-investigation of the underlying conduct; the extraordinary cooperation provided by the company to the department, the SEC and multiple foreign enforcement authorities, including significant assistance in the industry-wide investigation; and the extensive remedial efforts and compliance improvements undertaken by the company. In addition, J&J received a reduction in its criminal fine as a result of its cooperation in the ongoing investigation of other companies and individuals, as outlined in the U.S. Sentencing Guidelines. J&J's fine was also reduced in light of its anticipated resolution in the United Kingdom. Due to J&J's pre-existing compliance and ethics programs, extensive remediation, and improvement of its compliance systems and internal controls, as well as the enhanced compliance undertakings included in the agreement, J&J was not required to retain a corporate monitor, but it must report to the department on implementation of its remediation and enhanced compliance efforts every six months for the duration of the agreement. In a related matter, J&J reached a settlement with the SEC under which it agreed to pay


4








more than $48.6 million in disgorgement of profits, including pre-judgment interest.

Centocor Inc 12/1/2001 $19.42 Professional Practices Medical/Healthcare 03-60526-4 Texas

Woman took drug that caused lupus, sues Drug Company: In December 2001, plaintiff Patricia Hamilton, 47, a substitute teacher, began treatment for Crohn's disease on the orders of Dr. Ronald Hauptman. She visited the offices of Dr. Michael Bullen, who ran an infusion center in Corpus Chrisi, where she was treated with an infusion of Remicade, a medication used for the treatment of Crohn's disease and joint pain. Remicade is made by Centocor Inc., Horsham, Pa., a subsidiary of Johnson & Johnson, New Brunswick, N.J. After the second infusion, Hamilton began experiencing more severe joint and muscle pain. She went to see a rheumatologist, Adrianna Pop-Moody, who kept Hamilton on Remicade and also treated her with steroids for the joint pain. Hamilton was led to believe she had rheumatoid arthritis caused by the Remicade, but she since she got relief for a while from her Crohn's disease symptoms and joint pain, she attributed the relief to the Remicade. Thereafter, however, she continued to suffer joint pain and weakness despite decreased intervals between infusions and increased doses of Remicade. In January 2003, Hamilton was diagnosed with pericarditis, which is an inflammation of a sac around the heart. Pop-Moody suggested that Hamilton may have also developed drug-induced lupus. Hamilton continued on Remicade until September 2003, when the diagnosis of drug-induced lupus was confirmed by Houston doctors. She also had liver and gallbladder problems. After she stopped taking Remicade, the symptoms of lupus disappeared. In 2004, Hamilton sued Centocor Inc., Bullen, Hauptman and Pop-Moody, alleging that the defendants failed to adequately warn doctors or patients about the risks of taking the drug. The plaintiff contended that Centocor officials knew that Remicade carried the risk of drug-induced lupus but downplayed the risks to doctors. Furthermore, even though the company said that no new cases of lupus were reported, the plaintiff produced evidence showing 200 cases of drug-induced lupus that had been reported. Moreover, Hamilton alleged that doctors did not obtain her informed consent before they gave her the drug. Counsel also argued that Centocor misled the doctors and the public in its marketing of Remicade because Centocor marketed the drug with "feel good" videos that glossed over the risks of the drug. Hamilton herself was shown the video, which contributed to her decision to continue taking the drug, she claimed. The video, plaintiff's counsel argued, influenced patients to "demand" the drug from doctors. Counsel for Centocor argued that it made the risks of the drug known to the doctors and that if there were any liability, it lay with the doctors, whose responsibility it was to warn Hamilton about the risks. Counsel for the doctors argued that they informed Hamilton of the risk, an assertion plaintiff denied. A directed verdict was awarded in favor of Bullen. Hamilton claimed that she was unable to perform basic day-to-day functions, due to the pain in her joints. The drug left her with an increased risk of liver failure. She sought $65,908 in medical expenses, $5,000,000 for pain and suffering, mental anguish and physical impairment, as well as $15 million in punitive damages. Mr. Hamilton sought $500,000 for loss of consortium and $500,000 in punitive damages. Plaintiff and Pop-Moody entered into a $45,000 to $50,000 high-low settlement prior to jury submission. The jury returned a verdict in favor of the plaintiff, finding that Centocor hid the side effects of Remicade, and that Pop-Moody and Hauptman failed to properly warn Hamilton about the drug's dangers; the jury alloted 85 percent liability to Centocor, 10 percent to Pop-Moody and 5 percent to Hauptman. Hamilton was awarded $18,365,908, and her husband was awarded $1,050,000. According to counsel, the verdict is the first ever involving Remicade, which is Johnson & Johnson's second-largest drug by sales, and, to his knowledge, this is the first case in which a drug company was found liable for false direct marketing to a patient. Defense motions for judgment notwithstanding the verdict were denied. According to plaintiff's counsel, the court ruled that Dr. Hauptman, as the original tortfeasor, is responsible for the negligence caused by the subsequent treated, Dr. Pop-Moody, therefore, Hauptman will be liable for 15 percent. Patricia Hamilton $65,908 Personal Injury: Past Medical Cost $1,100,000 Personal Injury: Past Physical Impairment $1,200,000 Personal Injury: Past Pain and Suffering $1,000,000 Personal Injury: Future Pain and Suffering $15,000,000 Personal Injury: Exemplary damages Thomas Hamilton $50,000 Personal Injury: Past Loss of Consortium $1,000,000 Personal Injury: Exemplary damages.

ALZA Corp. 4/26/1993 $3.40 Securities Securities Class Action C-93-20290-RMW(PVT) California

A settlement of Class Claims in the amount of $3,400,000 and a favorable allocation to ALZA of the sums paid into the Settlement Fund by or on behalf of the Individual Defendants in settlement of the Derivative Claims asserted in the captioned litigation has been reached by the parties, The cases were consolidated as In re ALZA Securities Litigation, Master File C-93-20290-RMW(PVT) by stipulation and order filed May 26, 1993. A First Consolidated Amended Class Action Complaint For Violations of 10(b) and 20(a) of The Exchange Act of 1934, For Supplemental California State Law Claims, and Restated Demand For Jury Trial was filed on June 23, 1993. The Class Complaint asserts violations of 10(b) and 20(a) of the Securities Exchange Act of 1934, Rule 10b-5 promulgated thereunder and supplemental California state law claims. The Class Complaint names as defendants ALZA, Alejandro Zaffaroni, Martin S. Gerstel, Dr. Jane E. Shaw, Dr. Felix Theeuwes, Dr. Gary V. Fulscher, David R. Hoffmann, Julian N. Stern, Isaac Stein, Robert Glaser, Terry Burkoth, Arnold Kaufman, Gary S. Lyman, Pieter P. Bonsen, Dean Morton and Adrian M. Gerber. On July 9, 1993, Jolien Lou v. Zaffaroni, et al., (Case No. 732914), a Verified Derivative Complaint For Breach of Fiduciary Duty For Insider Trading, Gross Mismanagement, Abuse of Control, Waste of Corporate Assets, Unjust Enrichment And For Injunctive Relief And Damages was filed in the Superior Court of the State of California, County of Santa Clara (the

Neutrogena Corp. 8/11/1994 $1.75 Securities Securities Class Action 94-5492-LGB(JRx) California

False and misleading statements about the stock price of Neutrogena. Neutrogena's CFO stated on 8/10/94 that he knew of no reason for the sudden rise in Neutrogena's stock price which sent the stock tumbling. However, Neutrogena announced shortly after that they were engaged in merger talks with a larger company.

Ethicon Endo-Surgery, Inc.

$0.54 Professional Practices Medical/Healthcare 2001-60541-393 Texas

Plaintiff alleged stapler was cause of resection's rupture On Feb. 7, 2000, plaintiff Dianne Meyer, 50s, underwent a diagnostic laparoscopy by Curtis Mosier, M.D., at Denton Community Hospital; she had been having abdominal pain. The abdominal sutures ruptured, resulting in strangulation of the small intestine and in peritonitis. On Feb. 9 Mosier performed a resection, in which a surgical stapler was used to cut and reconnect the strangled intestine. Later observation revealed that one of the staple lines had dehisced, or ruptured, and bowel contents had leaked into the abdomen. Her recovery was long and difficult. Meyer sued Mosier; the hospital; and the company that made the stapler, Ethicon Endo Surgery Inc., Cincinnati, a Johnson & Johnson subsidiary. The hospital was dismissed early in the case. The stapler that Mosier used was a linear cutter. It was designed two deliver two double-staggered rows of staples while simultaneously dividing the tissue between the rows. Against Ethicon, Meyer alleged defective marketing of the TLC55 Proximate disposable linear cutter. She alleged that the company failed to warn physicians of the possibility of catastrophic staple-line failure, and she introduced evidence of 73 prior occurrences that she alleged were similar to this one. She also alleged unknown latent manufacturing and design defects. According to Meyer's attorneys, in early 1999, Ethicon had moved its TLC55 manufacturing facility to Mexico, at which time the number of injuries alleged to be related to the product spiked upward. Ethicon argued that the product was safe; that there are other causes of staple-line separation; and that it was not necessary to warn Mosier about a danger he knew of already. Regarding the claim against Mosier, Meyer's expert testified that Meyer was not a candidate for diagnostic laparoscopy, and that Mosier was therefore negligent for performing that surgery. The expert further testified that Mosier was negligent for failing to tie off the fascia in that surgery, and for using the stapler in the bowel resection when it would have been safer to do a temporary colostomy. Meyer's sutures ruptured, and the intestine was strangled in the opening. She developed peritonitis and had to undergo a bowel resection. Then a staple line dehisced, and bowel contents entered the abdomen, causing her to develop peritonitis again. She remained in the hospital for nearly six months and underwent several operations to cleanse the infected area. She claimed permanent fecal incontinence. According to Meyer, the past medical bills that resulted from the staple-line failure were $538,000. She also claimed future medical bills and past and future pain and suffering. The hospital was dismissed early in the case, and Mosier settled for an undisclosed amount a week before trial. The jury found marketing defect by Ethicon and awarded Meyer $538,000, all for past medical expenses. The jury found no manufacturing or design defect. The defense intends to appeal.

OraPharma, Inc. 11/8/2001 $0.35 Securities Securities Class Action 01 Civ. 9918 (Sas) New York

According to the Form 10-Q for the quarter ended September 30, 2002, in June and July 2002, all defendants filed motions to dismiss all the consolidated, amended complaints on numerous bases. In October 2002 the District Court approved and entered a stipulated order dismissing without prejudice all claims against the Company's officers in these cases pending against the Company. According to a Press Release dated November 9, 2001, a complaint was filed alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. On or about March 9, 2000, OraPharma commenced an initial public offering of 4,000,000 of its shares of common stock at an offering price of $17 per share (the 'OraPharma IPO'). In connection therewith, OraPharma filed a registration statement, which incorporated a prospectus (the


5








'Prospectus'), with the SEC. The complaint further alleges that the Prospectus was materially false and misleading because it failed to disclose, among other things, that: (i) the Underwriters had solicited and received excessive and undisclosed commissions from certain investors in exchange for which the Underwriters allocated to those investors material portions of the restricted number of OraPharma shares issued in connection with the OraPharma IPO and (ii) the Underwriters had entered into agreements with customers whereby the Underwriters agreed to allocate OraPharma shares to those customers in the OraPharma IPO in exchange for which the customers agreed to purchase additional OraPharma shares in the aftermarket at pre-determined prices. The securities issuers have settled their cases for a total of $586 million, allocated from the settlement fund.

Cordis Corp. 10/20/1995 $0.05 Securities Securities Class Action #unknown Florida

Breach of fiduciary duty in connection with Cordis' failure to consider a takeover offer by Johnson & Johnson. Cordis' directors failed to maximize shareholder value.

Johnson & Johnson 5/17/1995 $0.00 Employment Discrimination & Harassment: Gender/Sexual

MER-L-002020-96 New Jersey

Plaintiff Setareh Marvasti, a 49-year-old Iranian-born scientist for defendant Johnson & Johnson, alleged that she was terminated because of her national origin, color, gender and age in violation of the New Jersey Law Against Discrimination (NJLAD). She claimed that Johnson & Johnson unlawfully discriminated against her by denying her a promotion from principal scientist to research fellow and by terminating her on May 17, 1995. Marvasti charged that had she not been denied the promotion, she would have been the first female research fellow in the division, as well as in the entire consumer products sector of defendant J&J. Plaintiff also contended that she was discharged in retaliation for her complaints about the company's failure to promote her. She also asserted a claim for breach of implied contract. Marvasti maintained that defendant Alyson Keyes mistook her for being Indian and criticized her for not behaving consistently with female Indian stereotypes, while counseling her on diversity issues. Moreover, plaintiff asserted that Keyes also humiliated and imitated her for having "eyes that go round."Marvasti alleged that after her termination, she involuntarily left the company on June 2, 1995. She claimed that of all the employees discharged from the defendant J&J's analytical division at or about the time of her termination, almost 90 percent were over 40 years old and of the terminated people over 40, 100 percent were female or another minority. Defendants denied all of the plaintiff's allegations, asserting that reasonable factors other than plaintiff's age, sex and national origin were relied on in making the decision to terminate her employment. Defendants alleged that no one ever promised Marvasti that she would be promoted to the position of research fellow. Moreover, at trial, defense counsel cited Marvasti''s lack of patents and alleged improper keeping of her lab notebook as indications that she was not qualified for the new position. Defendants also contended that plaintiff was employed as an at-will employee; thus, she could be terminated at any time with or without notice and with or without cause. Finally, defendants maintained that the plaintiff's contract claims are barred for failure to show that there was consideration. The jury found that Marvasti was not qualified for the promotion that she was denied. Negotiations:Settlement: No cause of action upon which relief may be granted.Jury: (8/0). It was an eight-member jury, which was made up of four men and four women. There were two African-Americans and six whites. Among the panel, there was a male attorney, a female guidance department employee for Princeton University, a female homemaker, a female retiree, a male maintenance employee and a male paramedic who went to Ground Zero during the trial causing a delay of several days. There was no one on the jury who was under the age of 40.Note: After Sept. 11, Judge Paulette Sapp-Peterson queried the jury about whether the attacks would affect its ability to be fair and later instructed the jurors to disregard the attacks in their deliberations.Plaintiff's attorney Andrew Dwyer contended that he expected the trial to take two to three months. Instead, it took four months to put on his case. He maintained that Marvasti''s testimony alone took more than a month and went to re-re-cross-examination. Dwyer attributed the length of the case to its complexity and numerous interruptions, including a two-week break in August for vacation and the brief hiatus after the Sept. 11 attacks. Moreover, he cited that juror fatigue could also have been a factor in the trial's eventual outcome.

Johnson & Johnson 8/21/2009 Management & Strategy

ERISA violations 1:2011cv22587 Florida

On July 20, 2011, Plaintiff Roger Toledo (Toledo) filed a complaint in the U.S. District Court for the Southern District of Florida, against Defendant of Johnson & Johnson for its Long Term Disability Plan (Plan), alleging wrongful termination of benefits in violation of the Employee Retirement Security Act (ERISA). Plaintiff Toledo was a former employee of Defendant Johnson & Johnson, and was insured with the Plan, which was administered by the Pension Committee of Defendant and governed by the ERISA. Under the terms of the Plan, Defendant is obliged to pay its eligible group members long term disability benefits due to injury or sickness, including mental health illness. On March 19, 2008, Plaintiff became ill, ceased working, and sought benefits for the Defendant, which was initially accepted and commenced payments under the Plan. However, on August 21, 2009, without justification and in violation of the terms of the Plan, Defendant denied Plaintiff's continuing long term disability benefits. Plaintiff appealed with respect to his Plan's termination of benefits, and has complied with all prerequisites identified by and required by Defendant's benefit's administrator, but on September 9, 2009, he received a final denial letter from the Johnson Plan Pension Committee. Plaintiff seeks judgment against Defendant Johnson & Johnson and Affiliated Companies for full and complete reimbursement of all long term disability benefits, for attorneys' fees and costs, and declaratory judgment to have his long term disability benefits reinstated in accordance with the terms of the Plan.

Johnson & Johnson 1/1/2009 Employment Discrimination & Harassment: Appearance

3:12-cv-00779-JAP-LHG New Jersey

On February 9, 2012, a complaint was filed by Shamita Alwani Kumar (plaintiff) against Johnson & Johnson, Inc., ETHICON and Johnson & Johnson Consumer Products, Inc. (defendants) in the US District Court for the District of New Jersey alleging employment discrimination. According to the complaint, plaintiff was an employee of Johnson & Johnson from 2001 until 2011. Throughout that period of time, plaintiff held a variety of human resource, employee development and employee talent positions for Ethicon and Johnson & Johnson Consumer Products. While employed with Johnson & Johnson, plaintiff encountered discrimination on the basis of gender, national origin and color. She also experienced unequal pay as compared to comparably placed male employees. Plaintiff was retaliated against for exercising her right to take a parental leave in late 2009 and early 2010 and was also retaliated against for complaining about gender discrimination in Johnson & Johnson's workplace. As a result of this discrimination and retaliation, plaintiff was paid less than similarly situated male, non-southeast Asian employees, was unable to receive comparable promotions and titles and was demoted after taking a protected maternity leave. As a result of this conduct, plaintiff was ultimately terminated from her employment. The complaint charged the defendants with violations of the 1964 Civil Rights Act, Equal Pay Act and Family Medical Leave Act. The plaintiff seeks for an award of compensatory damages, reasonable costs, expenses and other relief.

Johnson & Johnson 12/1/2008 Business & Trade Practices


Undisclosed Oregon

On January 12, 2011, a lawsuit was filed by the Oregon Attorney General's Office against Johnson and Johnson and its McNeil Consumer Healthcare subsidiary alleging of not announcing a recall that would have warned the public about defective batches of Mortrin in late 2008. The company conducted a stealth buy back of the drug from store shelves and kept the problem quiet. The Mortrin was not officially recalled until 2010. The charges of the so-called 'phantom recall' first came up at a Congressional hearing last year after a massive Johnson & Johnson children's medication recall issued last April that affected 40 different liquid medications, including Motrin, Tylenol, Benadryl and Zyrtec. The company's actions have led congress to begin considering giving the FDA expanded drug regulatory powers. Oregon's lawsuit, filed in Multnomah County Circuit Court, says that Johnson & Johnson discovered there were problems with supplies of Motrin sold in 8 and 24 count containers in late 2008. The caplets did not dissolve properly, which meant that consumers may not receive the expected dose. According to the lawsuit, McNeil chose not to inform the public of a recall and instead hired contractors to go into stores and secretly buy all the affected Motrin without telling the public or sellers. According to the Oregon Attorney General's Office, one of the company documents gave the following instructions to contractors: "You should simply 'act' like a regular customer while making these purchases. THERE MUST BE NO MENTION OF THIS BEING A RECALL OF THE PRODUCT! If asked, simply state that your employer is checking the distribution chain of this product and needs to have some of it purchased for the project." One of the buyers became concerned about the orders being given by McNeil and alerted the Oregon Board of Pharmacy, which then notified the FDA. An official recall was still not announced until February 2010. The Oregon lawsuit charges the drug maker with violating the state's Unlawful Trade Practices Act (UTPA) on several counts, such as employing unconscionable tactics, making false or misleading representations and failing to disclose certain information. The counts carry a maximum penalty of $25,000 each.


6








Centocor, Inc. 10/1/2007 Cyber/Identity Risks Data Lost or Stolen

Stolen laptop contained Centocor speaker-consultant information: Several computers are missing from Centocor facilities in Horsham, Pennsylvania, of which one contained sensitive personal information belonging to speaker-consultants engaged by Centocor for the National Faculty and Rounds on the Road speakers programs. Centocor was notified by their IT vendor of the missing computers in early October, 2007, and was provided additional details on November 29th, 2007. (January 29, 2008 - breachblog.com)

Johnson & Johnson 5/24/2007 Cyber/Identity Risks Data/System Security Breach

Johnson & Johnson Breach: Alta Resources Corporation is a vendor engaged by McNEIL for product fulfillment purposes. The credit card information of some customers who ordered products from a McNEIL web site may have been exposed to persons outside of Alta by a former Alta employee. This exposure has been under investigation by federal law enforcement since May 24, 2007, and approximately two weeks after that, Alta provided McNEIL with a list of customers that had been affected by the foregoing breach. Alta has since implemented the PCI Data Security Standard which is a widely accepted industry standard. In mid- to late June, 2007, it ",'as determined that certain additional individuals may have been affected b)' the breach of security. (July 9, 2007 - doj.nh.gov)

McNEIL-PPC, Inc. 5/24/2007 Cyber/Identity Risks Unauthorized Data Distribution

McNEIL-PPC, Inc. Security Breach: Alta Resources Corporation is a vendor engaged by McNEIL for product fulfillment purposes. The credit card information of some customers who ordered products from a McNEIL web site may have been exposed to persons outside of Alta by a former Alta employee. This exposure has been under investigation by federal Law enforcement since May 24, 2007, and approximately two weeks after that, Alta provided McNEIL with a list of customers that had been affected by the foregoing breach. Alta has since implemented the PCI Data Security Standard which is a widely accepted industry standard. (June 20, 2007 - doj.nh.gov)

Ortho-Clinical Diagnostics, Inc.

5/1/2007 Cyber/Identity Risks Unauthorized Data Distribution

Ortho-Clinical Diagnostics employee info exposed: Almost 4,300 Ortho-Clinical Diagnostics, Inc. employees had their personal information exposed to employees with access to the company network after the security settings on a file that was supposed to restrict access to Human Resources Dept. personnel was inadvertently removed. The file was exposed for approximately six months. The personal information on employees dating back to 2002 may have included home address and telephone number, pre-employment screening information, compensation and other employment data, and social security number. Ortho-Clinical Diagnostics, Inc. is a subdivision of Johnson & Johnson, and the file was available to any authorized user of the Johnson & Johnson (North America). OCD arranged for free credit monitoring services for those affected. (December 3, 2007 - Privacy News)

Johnson & Johnson 7/22/2005 Employment Discrimination & Harassment: Age

2:05-cv-03663-KSH-PS New Jersey

Senior accountaint said he was denied promotions unfairly From July 23, 2003, through July 22, 2005, plaintiff Michael Richards, 43, while employed as a Senior Financial Analyst (accountant) with the Johnson and Johnson Consumer Products Company, a Division of Johnson & Johnson, applied for and was not selected for four positions with the company. Richards is an Asian-American who was born in Sri Lanka and became a naturalized American Citizen. Richards had previously worked for another division of Johnson & Johnson in which he did not have any problems with his supervisors or co-workers. Richards claimed he was given downgraded performance reviews and denied promotions because of his age, his race and in retaliation for previous complaints he had made about discrimination and accounting irregularities. After pursuing remedies with the U.S. Equal Employment Opportunity Commission, Richards sued his employer for employment discrimination. The defendants denied discrimination or retaliation in any form and produced evidence that it had properly investigated the plaintiff's prior complaints and found they lacked merit. The defense also defended its business decisions with respect to the plaintiff's performance reviews and applications for promotion and transfer to other positions. In addition to the statutory remedies for damages, both compensatory and punitive, the plaintiff sought compensation for the salary increases, bonuses and recognition for his accomplishments that he maintained he deserved. The defense maintained that the plaintiff was at all times adequately compensated for the work performed and had not received any diminishment of compensation during the tenure of his employment. The jury found that Richards failed to prove he was subject to age or race bias and that the company did not discriminate or retaliate against him in performance reviews.

Johnson & Johnson 8/8/2003 Employment Discrimination & Harassment: Racial

HUD-L-6196-04 New Jersey

Defense claims worker fired for poor performance In August 2003, plaintiff Fernando Portes, 40s, manager of global resources, was fired by his employer Johnson & Johnson Pharmaceutical Research and Development, LLC, a subsidiary of Johnson & Johnson. Prior to his dismissal, Portes, who had been born in the Dominican Republic, had filed a complaint with the EEOC claiming that Johnson & Johnson had discriminated against him on the basis of his Hispanic origin. Portes sued Johnson & Johnson, as well as Johnson & Johnson Pharmaceutical, alleging discrimination and retaliation under the New Jersey civil rights statutes. Plaintiff's counsel claimed that Portes was held to a higher standard of performance and denied other management positions because he was Hispanic. Counsel also claimed that a supervisor had mocked his accent on occasion. Defense counsel countered that Portes' employment had been terminated due to poor performance. Portes sought damages for emotional distress. He also claimed economic loss and sought to recover back and front pay and lost benefits, as well as court costs and attorney fees. The jury found that neither defendant had discriminated or retaliated against Portes because of his Hispanic origins. Plaintiffs counsel has filed a notice of appeal.

Centocor, Inc. 10/1/2001 Employment Discrimination & Harassment: Age

05-3080 Illinois

M. Jane Minor was a sales representative for Centocor, pitching to physicians and hospitals the products that Centocor and its affiliates offered to treat vascular conditions. After Antonio Siciliano became her supervisor, Minor contends, she was put in an impossible situation Siciliano required her to visit all of her accounts twice a month, and her major accounts more frequently. That led her to work 70 to 90 hours a week (much of it driving time); until then 50 to 55 hours had been enough. In August 2001, after two months of this regimen, Minor began to experience atrial fibrillation and depression. In October 2001 she stopped working. Both Centocor and the Social Security Administration have concluded that Minor is disabled (she receives benefits from both sources). She attributes her medical problems to Siciliano s demands. In this litigation Minor contends that those demands reflected both age and sex discrimination, violating the Age Discrimination in Employment Act and Title VII of the Civil Rights Act of 1964. (Minor has sued not only Centocor but also its corporate parent, which is not a proper party. Worth v. Tyer, 276 F.3d 249, 259-60 (7th Cir. 2001). We treat Centocor as the only defendant.) Minor wants the court to award the difference between her disability benefits and what she could have made had she remained in the work force. (Her lawyer related at oral argument that she does not seek any other recovery.) Nothing in the record so much as hints that Centocor in general, or Siciliano in particular, is biased against women or older workers, so Minor proposes to use the indirect method of proof pioneered by McDonnell Douglas Corp. v. Green, 411 U.S. 792 (1973). The district court concluded, however, that Minor had not established a prima facie case under that method because Centocor did not take any adverse employment action against her. Minor was not fired or demoted; she is still Centocor s employee, welcome to resume work if her condition improves. The events of which she complains not only the schedule for visiting accounts but also being bombarded by email messages from Siciliano and being subject to criticism and close supervision are the ordinary incidents of employment rather than adverse actions, the judge concluded in granting summary judgment for Centocor.

Johnson & Johnson 11/15/1999 Employment Discrimination & Harassment: Racial

01-5302 New Jersey

On November 15, 2001, Plaintiffs Med an employment discrimination suit on behalf of themselves and other similarly situated employees against Johnson & Johnson pursuant to Section 1981 of the Civil Rights Act of 1871, as amended by the Civil Rights Act of 1991, 42 U.S.C. 1981, Title VII of the Civil Rights Act of 1964, as amended by the Civil Rights Act of 1991, 42 U.S.C. 2000e et seq., and the New Jersey Law Against Discrimination, N.J. Stat. 10:5-1 et seq. Plaintiffs allege both disparate treatment (pattern or practice) and disparate impact. Plaintiffs have subsequently filed an amended complaint and a second amended complaint. After conducting extensive discovery, Plaintiffs filed a motion for class certification on September 27, 2004 and asked this Court to certify the following class of approximately 8,600 class members: All persons of African and/or Hispanic descent employed by defendant Johnson & Johnson in any


7








permanent salaried exempt or non-exempt position in the United States from November 15, 1997 to the present. Both parties then moved to strike the expert statistical report of their adversary. On November 6, 2006, this Court denied Plaintiffs' motion to strike the expert report of Dr. David Wise ("Wise Report") and Defendant's motion to strike the expert report of Drs. Madden & Vekker ("Madden Report"). Gutierrez v. Johnson & Johnson, 01-cv-5302, 2006 WL 3246605 (D.N.J. Nov. 6, 2006). The Court heard oral argument on the motion for class certification on December 5, 2006. On December 19, 2008, the Court denied the plaintiffs motion for class certification. The Court concludes that Plaintiffs fail to meet their burden to demonstrate commonality, typicality, and adequacy.

Neutrogena Corporation 3/22/2012 Business & Trade Practices

Marketing Practices Unknown California

On March 23, 2012, two consumers targeted Neutrogena Corp. with a putative class action in California state court on March 22, alleging that the skin care company has raked in profits by falsely advertising that two of its anti-wrinkle moisturizers visibly reduce wrinkles within one week. Lead plaintiffs Stephanie Johns and Sara Fabie allege that despite Neutrogena's claim in advertisements and on product packaging that the lotions, Rapid Wrinkle Repair Night Moisturizer and Rapid Wrinkle Repair Moisturizer SPF 30, are clinically proven to reduce the appearance of wrinkles.

Neutrogena Corporation 1/28/2012 Business & Trade Practices

Marketing Practices 3:12-cv-00426 California

On January 28, 2012, Desiree Stephenson filed a complaint against Neutrogena Corporation in the U.S. District Court California Northern District. Plaintiff alleges defendant for deceptive and unlawful business practices of defendant's marketing and sales of Neutrogena Naturals. Defendant manufactures sells and distributes the products using a marketing and advertising campaign that is centered on claims that the products are natural. However, Defendant's advertising and marketing campaign is false and misleading because the products contain various artificial and synthetic ingredients such as sodium benzoate, undefined yet chemically derived. Plaintiff relied on defendant's misrepresentation that the products were Natural when purchasing the products. Plaintiff and the proposed class paid a premium for the products over comparable products that did not purport to be natural. As a result plaintiff seeks an order enjoining defendant acts of unfair competition and awarding restitution to the individual victims of defendant unfair and deceptive practices. Also, plaintiff seeks damages under CLRA.


Marketing Practices 137436 Quebec

On September 20, 2011 Nick Field filed a proposed class action in the Supreme Court of British Colombi against Johnson & Johnson, Johnson & Johnson Inc. and Mcneil Consumer Healthcare Canada (collectively J&J). The action involves brands of infants' and children's over-the-counter (OTC) drugs manufactured, improted and sold in violation of the Food and Drug Act (FDA) and Regulations (FDR). The action was brought in connection to J&J's alleged false representations to consumers that their products complied with the FDA and FDR, and were manufactured consistent with US cGMPs as a basis of inducing consumers to purchase their products in breach of the British Columbia Business Practices and Consumer Protection Act (BPCPA). The Plaintiff alleges that the false representations and deceptive practices of J&J resulted in damages and loss to the plaintiff and a class of similarly situated individuals. The plaintiff sought the certification of this case as a class proceeding, declaration, permanent injucnction, order J&J to advertise adverse findings against them, disgorgement and/or restitution, constructive trust, damages, investigation costs, punitive damages and other relief.

Johnson & Johnson 9/1/2011 Securities Derivative Shareholder Action

3:11-cv-05084-JAP -DEA

New Jersey

On September 1, 2011, The George Leon Family Trust filed a lawsuit on behalf of the nominal defendant Johnson & Johnson (J&J or Company) in the U.S. District Court of New Jersey against certain of the officers and directors of the Company alleging claims of breach of fiduciary duties of candor, good faith and loyalty, and for corporate waste and unjust enrichment, including the issuance of false and misleading statements in the J&J's annual proxy statements since 2008. The action arises from the defendants' failure to follow J&J's executive compensation philosophy, and J&J's guiding principles for executive compensation. In failing to follow J&J's executive compensation policies and procedures, the defendants have breached their duty of loyalty and candor, thus grossly over-compensating the CEO of the company, whose total compensation now exceeds $150 million for the period 2006 to present. The plaintiff seeks an extraordinary equitable and/or injunctive relief, equity and statutory provisions, including disgorgement, attachment, impoundment, imposition of a constructive trust on or otherwise restricting the disposition/exercise of improvidently awarded executive compensation that was disconnected with pay for performance principles, or the manner of performance, so as to ensure that the plaintiff on behalf of the company has an effective remedy. The plaintiff also seeks an award on the costs and disbursements of the action, including reasonable attorneys' fees and costs.


3:11-cv-04994 New Jersey

On August 29, 2011, a derivative shareholder complaint was filed by Leslie Katz (the Plaintiff) against Johnson & Johnson (The Company or J&J), its executives and directors in the United States District Court District of New Jersey. The action was brought to cause the Company to meet the standards imposed by federal law and those expected of a company entrusted with the public's safety in manufacturing certain of its over-the-counter ("OTC") drugs. The Plaintiff alleged that the McNeil-PPC, Inc. ("McNeil"), a wholly-owned subsidiary of the Company, has consistently failed to adhere to Current Good Manufacturing Practice ("CGMP") regulations promulgated by the Food and Drug Administration ("FDA") in producing several OTC drugs including Tylenol, Motrin, Sudafed, Benadryl and others. Then, when defective drugs were distributed endangering the health and safety of consumers, rather than publicly announcing and acknowledging its faulty conduct, the Company engaged in a stealth recall involving the surreptitious removal of the offending drugs from retail stores. The Plaintiff sought for an award of damages, pre-judgment interest against each defendant for restitution and/or damages in favor of plaintiff, directing J&J to take all necessary actions to reform and improve its corporate governance and internal control procedures and all other legal requirements to protect the company and its shareholders, costs and expenses, and other relief.


Marketing Practices 3:11-cv-01310 California

On June 14, 2011 a class action lawsuit was filed against Johnson & Johnson and McNeil Nutritionals, LLC (collectively the companies) alleging that the companies falsely advertise that their Benecol Spread and Benecol Light Spread are proven to reduce cholesterol. Benecol is a margarine-like spread that contains vegetable oils, and is marketed as Proven to Reduce Cholesterol because it contains plant stanol esters, a group of chemical compounds believed to reduce the level of low-density lipoprotein (LDL) cholesterol in blood when ingested under the correct circumstances. According to the lawsuit, however, there are no studies demonstrating that plant stanol esters have an impact on population-based CHD morbidity and mortality rates. The lawsuit also stated that the Food and Drug Administration (FDA) approved a detailed and highly qualified health claim for foods containing at least 1.7g of plant stanol esters per serving. Benecol, however, contains only 0.85g plant stanol esters per serving and does not qualify to display the FDA-approved health claim. Nevertheless, for over a decade, Johnson & Johnson has packaged Benecol with an improper plant stanol health claim, rendering Benecol misbranded under the Federal Food, Drug Cosmetic Act. The lawsuit also alleged that Benecol was made with partially hydrogenated vegetable oil (PHVO) containing artificial trans fat, a toxic food additive that, in the amounts present in Benecol, negatively affects blood cholesterol levels to a greater degree that any positive effect associated with plant sterol esters in the product. The companies have deceived the customers. The lawsuit sought restitution for proposed class of all persons who purchased Benecol Spread or Benecol Light Spread on or after January 1, 2000 in the United States for their own or household use. It also sought for injunctive relief for a proposed class of all persons who commonly purchase or are in the market for Benecol Spread or Benecol Light Spread in the United States for their own or household use.


3:2011cv02511 New Jersey

On May 2, 2011, a derivative shareholder action was filed by Sandra Wollman and Gila Heirmowitz, derivatively on behalf of Johnson & Johnson (J&J or the Company) in the U.S. District Court for the District of New Jersey against Johnson & Johnson directors for breach of fiduciary duty, mismanagement, abuse of control, corporate waste, unjust enrichment and violations of the federal securities laws. According to the lawsuit, on April 7, 2011, J&J shareholders learned that J&J has engaged in a wide stream scheme to bribe doctors in Europe and pay kickbacks to Iraq in order to win contracts to sell drugs, artificial joints and other products. According to the United States Securities and Exchange Commission (SEC), J&J violated the Foreign Corrupt Practices Act (FCPA) because the company failed to implement internal controls to detect or prevent bribery. In total, J&J earned over $24 mln in profits by bribing Greek doctors to buy surgical implants. The Company earned $4.3 mln in Poland as a result of another bribe, and another $3.5 mln through illegal rewards in Romania. The company has also made $6.1 mln in profits by paying kickbacks to Iraq to win a business. J&J purportedly self-reported its potential violations of the FCPA in Greece, Poland and


8








Romania to the SEC and DOJ in February 2007. However, the company did not self-report its violation of the FCPA based on the kickbacks to Iraq. The Company never disclosed to its shareholders the details regarding the Company's widespread bribery of doctors in Europe and kickbacks to Iraq. On April 7-8, 2011, the SEC and DOJ announced that J&J had resolve federal FCPA enforcement actions against the Company by admitting to engaging in a scheme to bribe doctors on Europe and pay kickbacks to Iraq. The U.S. government also revealed that J&J agrees to pay $70 mln in disgorgement, interest and fines, in addition to entering into deferred prosecution agreement with the DOJ entailing substantial additional costs to the Company. Plaintiffs alleged that as J&J directors, the responsibility for causing J&J to implement the FCPA rests with the defendants. However, defendants failed to act with disastrous consequences for J&J. Defendants are therefore liable to J&J for all damages arising from breach of fiduciary duty, mismanagement, abuse of control, corporate waste, unjust enrichment and violations of the federal securities laws. Plaintiff sought to recover damages sustained by defendants' violations, exemplary damages and costs and disbursements of the action including reasonable attorneys' and expert fees, costs and expenses. On July 29, 2011, the court ordered that plaintiff motion to consolidate case filed on May 23, 2011, Civil Action No. 11-2652 and Civil Action No. 11-2511 is granted. That the consolidation actions shall bear the following caption: In re Johnson & Johnson FCPA Shareholder Derivative Litigation.

Depuy Inc 4/8/2011 Securities Foreign Corrupt Practices Act (SEC)

1:11-cr-00099-RBW District of Columbia

On April 8, 2011, a lawsuit was filed against a Johnson & Johnson (J&J) subsidiary, DePuy Inc. (Depuy), in the U.S. District Court in the District of Columbia alleging claims of conspiracy and violations of the Foreign Corrupt Practices Act (FCPA) in connection with the payments to public physicians in Greece. In November 1998, J&J acquired DePuy, including its subsidiary, DePuy International. From 1998 through 2006, within the territory of the United States and elsewhere, DePuy and others did unlawfully and knowingly combine, conspire, confederate, and agree to commit the following offenses against the United States. First is to offer, pay, promise to pay, and authorize the payment of money and other things of value, to a person, while knowing that all or a portion of such money or things of value would be offered, given, or promised, directly or indirectly, to foreign officials of Greece for purposes of (i) influencing acts and decisions of such foreign officials in their official capacities; (ii) inducing such foreign officials to do and omit to do acts in violation of the lawful duties of such officials; (iii) securing an improper advantage; and (iv) inducing such foreign officials to use their influence with a foreign government and instrumentalities thereof to affect and influence acts and decisions of such government and instrumentalities, in order to assist DePuy and others in obtaining and retaining business. Second is to knowingly falsify, and cause to be falsified, books, records, and accounts which were required, in reasonable detail, to accurately and fairly reflect the transactions and dispositions of the assets of J&J.


Marketing Practices 3:11-cv-00086 Oregon

On January 11, 2011, the State of Oregon filed a lawsuit in Multnomah County Circuit Court against Johnson & Johnson and its subsidiaries, McNeil-PPC and McNeil Healthcare. The lawsuit alleges multiple violations of Oregon's Unlawful Trade Practices Act (UTPA). Among other things, the UTPA prohibits employing unconscionable tactics, making certain false or misleading representations, or failing to disclose certain information. McNeil Consumer Healthcare, the Johnson & Johnson unit involved in several product recalls, had hired outside contractors to buy back vials of Motrin in early 2009 because the pills failed to dissolve properly, a problem that could diminish the product's effectiveness. McNeil-PPC and McNeil Healthcare discovered in late 2008 that supplies of Motrin sold in 8- and 24-caplet containers were defective, according to the lawsuit. The containers were sold at gas stations, truck stops and convenience stores. In Oregon, the stores were scattered from the Portland area to Medford. On Feb. 17, 2010, McNeil announced a recall of the 24-count vials from wholesalers and retailers. The Motrin buyback program came to light last year during an investigation into recent recalls of over-the-counter McNeil drugs by the House Committee on Oversight and Government Reform. McNeil recalled more than 200 million product units last year, including different kinds of Tylenol, Motrin and Rolaids. The Oregon lawsuit accuses Johnson & Johnson and McNeil of violating the state's unlawful trade practices act by misrepresenting the effectiveness and quality of the Motrin in question. It also accused the company of failing to disclose to consumers that the Motrin might have been ineffective. If the company were found liable, it could be fined up to $25,000 for each container of defective Motrin sold to a consumer in Oregon. On January 24, 2011, the case was transferred to the U.S. District Court of Oregon. On April 8, 2011, the district court entered an opinion and order staying the case pending for a possible transfer of action to the Recall MDL.

Johnson & Johnson Consumer Companies, Inc

11/24/2010 Business & Trade Practices

Marketing Practices 3:10-cv-06196-FLW -DEA

New Jersey

On November 24, 2010 Caryn Lieberson (plaintiff) filed a lawsuit in the New Jersey District Court against Johnson & Johnson Consumer Companies, Inc. (J&J or defendant) for false and misleading marketing practices. The defendant sells the products JOHNSON'S BEDTIME Bath ("Bedtime Bath"), JOHNSON'S BEDTIME Moisture Wash ("Bedtime Moisture Wash"), JOHNSON'S BEDTIME Lotion ("Bedtime Lotion"), and JOHNSON'S BEDTIME Baby Bubble & Wash ("Bedtime Baby Bubble & Wash") (collectively, the "Bedtime Bath Products"), which purport to help a baby sleep better. J&J markets and advertises the Bedtime Bath Products with the benefits of clinically proven to help baby sleep better, help babies fall asleep easier, and help babies sleep through the night, if used as part of a 3-step routine of a warm bath, gentle massage and quiet activities. As Defendant knows, no clinical studies demonstrate that using the Bedtime Bath Products with the 3-step routine is any more effective at helping babies sleep better than using the 3-step routine without the Bedtime Bath Products. As a result of its unsubstantiated claims, J&J charges a premium for Bedtime Bath Products, which Plaintiff and other consumers pay with the understanding, based upon Defendant's false and misleading representations, which using the Bedtime Bath Products in connection with the 3-step nighttime routine will help babies sleep better. As a result of these false and misleading representations, Plaintiff and consumers have paid more for the Bedtime Bath Products than they otherwise would have absent the wrongful conduct and have been damaged and suffered an ascertainable loss as a result of the wrongful conduct. The plaintiff seeks judgment, all recoverable compensatory and other damages, statutory damages for injuries suffered, and such other and further relief. On September 21, 2011, District Judge Freda L. Wolfson ordered that the plaintiff's allegations regarding the Bedtime Bath and Bedtime Baby Bubble & Wash are dismissed without prejudice for lack of standing.

Johnson & Johnson 9/21/2010 Securities Securities Class Action 3:10-cv-04841-FLW -DEA

New Jersey

On September 21, 2010, a class action complaint on behalf of who purchased Johnson & Johnson's (JNJ) securities between October 14, 2008 and July 21, 2010 (Class Period) was filed against JNJ, its certain officers and Peter Luther (President of McNeil-PPC, Inc.) in New Jersey District Court. According to the complaint, during the class period, defendants repeatedly touted the success and revenue of OTC drug sales by its subsidiary McNeil. At the same time, defendants failed to disclose that a number of manufacturing facilities were failing to maintain current good manufacturing practices (cGMPs). Specifically, defendants' Class Period statements were materially false and misleading for failing to disclose the following: (a) Starting in April of 2008, defendants received numerous consumer complaints that Tylenol products made at a manufacturing facility in Las Piedras, Puerto Rico exhibited a "musty" odor. Despite being aware of these complaints, defendants failed to conduct an adequate investigation and failed to notify the U.S. Food and Drug Administration (FDA) as required; (b) Defendants failed to take corrective action when foreign materials and contamination were found in a manufacturing facility in Fort Washington, Pennsylvania from May 2009 to April 2010. Similarly, defendants ignored 46 separate complaints of foreign materials in products made at that facility from June 2009 to April 2010; and (c) In late 2008, defendants learned of potential problems with one of its Motrin products. Rather than issue a public recall, defendants sent contractors out to stores to buy the product back and told the contractors not to mention any recall. After the FDA learned of this "phantom recall," it pressured defendants to publicly recall the products. As a result of the blatant, systemic, and repeated failure of defendants to maintain proper manufacturing practices at their facilities, defendants had been forced to issue over eight separate recalls including dozens of products and hundreds of millions of individual packages. Further, defendants are now under investigation by the U.S. House of Representatives, the U.S. Senate, and the U.S. Attorney's Office for the Eastern District of Pennsylvania, and multiple state Attorneys General offices. As a result of the gradual disclosure of defendants' conduct, the price of JNJ stock declined significantly, causing damages to Plaintiff and the Class. Accordingly, Monk seeks the complaint to proceed as a class-action and seeks unspecified damages. On December 06, 2010, the Court issued an Order Appointing Lead Plaintiff and Approving Lead Plaintiff's Selection of Lead Counsel and Liaison Counsel in this matter. On March 11, 2011, an amended complaint against all defendants was filed by the lead plaintiff. On May 27, 2011, a motion to dismiss was filed. However, on December 19, 2011, it was denied. On December 19, 2011, defendants William C. Weldon and Peter Luther were terminated from the case. On January 3, 2012, a motion for Reconsideration was filed regarding order on motion to dismiss.

McNeil-Ppc, Inc 7/26/2010 Business & Trade Practices

Marketing Practices 10 30400 Florida


9








On July 26, 2010 Tylenol buyers (consumers) filed a lawsuit against McNeil Consumer Healthcare a division of Mcneil-PPC Inc. (Mcneil) for false advertising and deception. McNeil manufactured, marketed and sold a product known as Tylenol PM (product). In the early 1990s, McNeil began marketing the product. The product was commonly advertised and marketed as a nighttime sleep aid for relief of occasional pain and discomfort associated with minor aches and pains. On February 16, 2010 the head of the Food and Drug Administration's (FDA) Office of Nonprescription products wrote a letter to the Consumer Health Products Association (CHPA) expressly stating that there is an insufficient basis to support the combination of acetaminophen and diphenhydramine as a nighttime sleep aid for relief of occasional sleeplessness when associated with minor aches and pains. As advertised on the packaging, the product contained acetaminophen and diphenhydramine and it was the combination of these ingredients that McNeil claimed constitutes a sleep aid and will give consumers a good night's rest. McNeil's advertisements, marketing materials and claims to consumers regarding the uses of the product are completely false and deceptive. McNeil's misleading marketing campaign begins with a deceptive name as it implied that it would make the consumer sleepy. McNeil's exhaustive advertising campaign build on this deception. In addition, McNeil have no competent and reliable support for these claims, even though it states that it was clinical proof. McNeil's representations are false and deceptive. According to the lawsuit, as a result of the deceptive and misleading messages conveyed through the campaign, Mcneil have been able to charge a significant price premium for Tylenon PM over other similar products. The class of the product consumers demanded restitution and disgorgement for violations of Florida's Deceptive and Unfair Trade Practices Act and breach of express warranty.

Micrus Endovascular Corp

7/16/2010 Securities Breach of Fiduciary Duties: Securities

Unknown California

On July 16, 2010, a lawsuit was filed by an investor of Micrus Endovascular Corp (Company/ Micrus Endovascular) (NASDAQ: MEND) against the Company and certain of its officers and/or directors in California State Court. According to the complaint, on July 12, 2010, the Company, which develops, manufactures and markets implantable and disposable medical devices used in the treatment of cerebral vascular diseases, and Johnson & Johnson (Johnson), announced an agreement whereby the Company will be acquired in cash for stock exchange. Under the terms of the agreement, the Company's stockholders will receive at closing $23.40 for each outstanding Micrus Endovascular share. The value of the transaction as of the anticipated closing date is estimated to be approximately $480 million. According to Micrus Endovascular its board of directors approved the transaction. The complaint alleges that the defendants breached their fiduciary duty by selling Micrus Endovascular though an unfair process and for an unfair price to Johnson. Shares of the Company traded before the news at $22.20 per share, and at $23.25 per share after the announcement. But the plaintiff claims that the Company's shares have nearly tripled over the past year and the offer, which represents a mere 5.5% premium over the closing price of the stock on July 09, 2010, of $22.19, is actually a significant discount to one analyst's target of $25.00 per share.


3:2010cv02033 New Jersey

In its November 7, 2005 Form 10-Q, J&J first disclosed that on September 26, 2005, the Company had received a subpoena from the United States Attorney's Office, District of Massachusetts, seeking documents related to sales and marketing of eight drugs to Omnicare, Inc., a manager of pharmaceutical benefits for long-term care facilities. On January 15, 2010, the United States Department of Justice announced that it had filed a civil False Claims Act complaint (the "Federal Kickback Complaint") against J&J and two of its subsidiaries, Ortho-McNeil-Janssen Pharmaceuticals Inc. and Johnson & Johnson Health Care Systems Inc. The Federal Kickback Complaint and all exhibits thereto are attached as Exhibits 1 through 4 hereto, and incorporated by reference herein. The Federal Kickback Complaint alleges that the Company and its subsidiaries, in violation of the federal anti-kickback statute, 42 U.S.C. 1320a-7b(b), paid millions of dollars in kickbacks to Omnicare Inc., ("Omnicare") thereby causing Omnicare, the nation's largest longterm care pharmacy, to submit false claims to Medicaid during the period from 1999 through 2004. On April 21, 2010 Jeanne M. Calamore filed a derivative action against Mary Sue Coleman, James G. Cullen, Robert J. Darretta, Russell C. Deyo, Alex Gorsky, Michael M.E. Johns, Ann Dibble Jordan, Arnold G. Langbo, James T. Lenehan, Susan L. Lindquist, Leo F. Mullin, William D. Perez, Christine A. Poon, Charles O. Prince, III, Steven S. Reinemund, David Satcher, Henry B. Schacht, Joseph C. Scodari, Ted Torphy, Nicholas Valeriani, William C. Weldon, Robert N. Wilson and Johnson & Johnson in the U.S. District Court District of New Jersey with Case No. 3:2010cv02033. The lawsuit claims against the defendants Breach of Fiduciary Duty in connection with the Omnicare Kickback Scheme, the Risperdal Off-Label Promotion Scheme, the Natrecor Off-Label Promotion Scheme, the Topamax Off-Label Promotion Scheme, the DePuy Kickback Scheme, the Biliary Stent Off-Label Promotion Scheme, and the Delayed OTC Contamination Recall Scheme. On June 30, 2011, Hawaii Laborers Pension Fund filed a motion to consolidate cases and a motion to appoint lead plaintiff. On August 17, 2010, the court ordered to consolidate cases. On December 17, 2010, the plaintiffs filed a consolidated amended complaint against the defendants. On February 21, 2011, the defendants moved for the dismissal of the consolidated amended complaint. On September 29, 2011, the Court issued an order granting the defendants' motion of dismissal. The complaint was dismissed without prejudice.

Depuy Inc 11/1/2009 Business & Trade Practices

Foreign Corrupt Practices Act (DoJ)

Unknown

On April 14, 2010, the U.K.'s Serious Fraud Office (SFO) announced that a former DePuy executive pleaded guilty to making u4.5 million in corrupt payments to Greek medical professionals within the state-controlled healthcare system. He was sentenced to 12 months in prison. Robert John Dougall was appointed Director of Marketing at DePuy in 1999. In 2000, he was given the responsibility for business development in Greece. The SFO alleges that from 2002 to 2005, Dougall was involved in corruptly obtaining and retaining business in the Greek orthopedic market by providing inducements/rewards to surgeons who would purchase DePuy products. DePuy allegedly used a local distributor to whom a commission was paid. DePuy and Dougall are alleged to have known that a portion of these commissions would be used to induce or reward surgeons to use DePuy products. Other corrupt payments were made through offshore agents and offshore accounts. Dougall was first charged by the SFO in November 2009. The investigation into Dougall and DePuy's actions commenced following a referral from the US Department of Justice in October 2007. The SFO noted that Dougall is the first "co-operating defendant" in a major SFO corruption investigation. He is fully co-operating with the SFO's continued investigation into the roles and involvement of others.

Cougar Biotechnology Inc

5/28/2009 Securities Breach of Fiduciary Duties: Class Action

Case No. BC 414586 California

Cougar Biotechnology, Inc. (NASDAQ: CGRB - News) announced the voluntary dismissal by the plaintiff of a class action complaint filed on May 28, 2009 in the Superior Court of the State of California, Los Angeles County. The complaint, captioned Puzanov v. Cougar Biotechnology, Inc., et al., Case No. BC 414586, sought to enjoin the tender offer commenced by Kite Merger Sub, Inc., a wholly owned subsidiary of Johnson & Johnson (NYSE: JNJ - News), for all of the outstanding shares of Cougar Biotechnology's common stock at a price of $43.00 per share. Cougar will pay no settlement or attorneys' fees or other expenses of the plaintiff in connection with dismissal of the complaint. Cougar also noted that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) applicable to the tender offer was terminated on June 17, 2009. The termination of the HSR waiting period satisfies one of the conditions of the tender offer. Completion of the tender offer remains subject to the tender of a majority of Cougar's outstanding shares of common stock on a fully diluted basis and the satisfaction of certain other conditions.

Mentor Corp 1/15/2009 Securities Breach of Fiduciary Duties: Class Action

Unknown Virginia

According to a press release on January 15, 2009 a Class Action lawsuit has been filed in the United States District Court for the Central District of California on behalf of a class consisting of all persons or entities who currently hold Mentor Corporation common stock. The Complaint charges certain of the Company's executive officers and directors with breaches of fiduciary duty in connection with Mentor's proposed acquisition by Johnson & Johnson by failing to maximize shareholder value. The Complaint cites an industry analyst who claims Johnson & Johnson "stole" the Company and "likely underpaid." In addition, the Complaint also charges certain Mentor executive officers and directors with self-dealing.

Mentor Corp 12/15/2008 Securities Breach of Fiduciary Duties: Class Action

Case No. 1304357 California

On December 1, 2008, Mentor Corporation entered into an Agreement and Plan of Merger with Johnson & Johnson, a New Jersey corporation and Maple Merger Sub, Inc., a Minnesota corporation and a wholly-owned subsidiary of Johnson & Johnson. Pursuant to the terms of the Merger Agreement, and subject to the conditions thereof, Johnson & Johnson has agreed to commence a cash tender offer to purchase all of the issued and outstanding shares of the common stock, par value $0.10 per share, of the Company at a per share purchase price of $31.00, for aggregate equity consideration of approximately $1.07 billion. The estimated net value of the transaction is $1.12 billion based on the Company's 34.6 million fully diluted shares outstanding, plus estimated net debt at the time of closing. Following the consummation of the Offer, Merger Sub will merge with and into the Company and the Company shall be the surviving corporation in the


10








Merger and shall continue its corporate existence under the Minnesota Business Corporations Act as a wholly-owned subsidiary of Johnson & Johnson. In connection with the Merger, the Shares, other than Shares held by the Company, Johnson & Johnson, Merger Sub or shareholders who have validly exercised their appraisal rights under the Minnesota Business Corporations Act, will be cancelled and will be automatically converted into the right to receive the Offer Price. On December 15, 2008, the Police and Fire Retirement System of the City of Detroit, alleging itself to be a shareholder of Mentor Corporation, filed a purported shareholder class action complaint in the Santa Barbara County Superior Court of the State of California, captioned Police and Fire Retirement System of the City of Detroit v. Mentor Corporation et al., Case No. 1304489, in connection with the Offer and Merger. The complaint names as defendants Mentor Corporation, the members of Mentor Corporation Board, certain Mentor Corporation officers, Johnson & Johnson, Ethicon and Does 1-25. The suit alleges that the members of Mentor Board and certain officers of Mentor breached their fiduciary duties to Mentor's shareholders in connection with the sale of Mentor, and that Mentor, Johnson & Johnson and Ethicon aided and abetted the purported breaches of fiduciary duties. The suit seeks various equitable relief related to the Offer and the Merger and also seeks the costs of the action, including reasonable allowances for attorneys' fees and experts' fees. Johnson & Johnson believes the allegations against Johnson & Johnson and Ethicon are without merit, and Johnson & Johnson intends to defend vigorously the action. On December 17, 2008, Cinotto v. Mentor Corporation et al., Case No. 1304357, and Steamfitters Local 449 Pension Fund v. Mentor Corporation et al., Case No. 1304364, were consolidated for all purposes as In re Mentor Corporation Shareholder Litigation, Lead Case No. 1304357, in Santa Barbara County Superior Court. On January 6, 2009, the court in In re Mentor Corporation Shareholder Litigation , Lead Case No. 1304357, ordered Police and Fire Retirement System of the City of Detroit v. Mentor Corporation et al. , Case No. 1304489, consolidated as part of In re Mentor Corporation Shareholder Litigation , Lead Case No. 1304357.

Micrus Endovascular Corporation

10/2/2007 Securities Securities Class Action 07-CV-22601 Florida

According to the Company's Form 10-K for the fiscal year ended March 31, 2008, on January 22, 2008, the Court appointed lead class plaintiff, and on February 6, 2008, plaintiffs filed their Consolidated Complaint. On February 26, 2008, the Company filed a Motion to Dismiss the Consolidated Complaint for failure to state a claim, and on May 20, 2008 the Court granted the Motion to Dismiss, giving plaintiffs ten days, until May 30, 2008, to amend their Complaint. Plaintiffs failed to amend their Complaint, and on June 6, 2008, the Court dismissed the case with prejudice. The original complaint charges Micrus and certain of its officers and directors with violations of the Exchange Act. Micrus develops, manufactures, and markets implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Specifically, the complaint alleges that defendants issued materially false and misleading statements during the Class Period and failed to disclose: (i) that sales at Micrus Design, one of the Company's key subsidiaries, were slowing dramatically and not meeting internal expectations as the subsidiary was encountering increasing competition; (ii) that the Company was experiencing increased regulatory issues in China and Japan which would delay and impede its ability to get its full complement of products approved for sale in those countries; and (iii) as a result of the foregoing, Defendants' positive statements about the Company, its earnings, products and prospects were lacking in a reasonable basis at all times and materially false and misleading. The complaint further alleges that on or around September 17, 2007, Micrus issued a press release announcing that it was revising its financial guidance and now expects fiscal 2008 revenues to be between $65 million and $75 million because of expected product approval delays in China as well as Japan and slower-than-anticipated sales in North America. In response to the announcement the price of Micrus common dropped from $23.57 per share to $17.37 per share on extremely heavy trading volume. A similar, purported class action complaint has also been filed in the U.S. District Court for the Northern District of California. June 6, 2008 the court issued a final order dismissing the lawsuit.

Johnson & Johnson 7/23/2002 Securities Securities Class Action 02-CV-03534 New Jersey

On October 15, 2004, the Court entered the Opinion and Order signed by U.S. District Judge William G. Bassler granting the motion to dismiss the plaintiffs' consolidated amended class action complaint. The civil case was terminated. The original complaint alleges that prior to the beginning of the Class Period there were reports of 40 cases of pure red cell aplasia ("PRCA") in chronic renal failure in patients taking EPREX, which is manufactured at Johnson & Johnson's Puerto Rico facility and sold in Europe. PRCA is a condition in which the body loses its ability to produce red blood cells, leaving the patient dependent on blood transfusions for survival. The Class Period begins on April 16, 2002 when defendants released Johnson & Johnson's first quarter results. In the Company's press release and during the earnings conference call held that day, defendants repeatedly attributed the Company's financial performance to the success of EPREX, stating, for example, that "This amazing product has delivered consistent double-digit growth over the past five years. And in the first quarter of this year, we hit a record sales level of a billion dollars." Moreover, defendants discussed the reported incidences of PRCA and assured investors that EPREX "continues to be a trusted brand that people are using," and that Johnson & Johnson was "working very closely with ... the experts, as well as health authorities in understanding (PRCA), why it occurs. And we're doing whatever we can to understand the risk and mitigate it." Then, the complaint alleges that defendants' statements during the Class Period, however, were materially false and misleading because defendants knew but failed to disclose that by April 2002, the U.S. Food and Drug Administration's Office of Criminal Investigation, spurred on by the increasing number of cases of PRCA in EPREX patients, sought a stay of a qui tam (whistleblower) action in order to investigate the allegations regarding the Company's EPREX manufacturing facility located in Puerto Rico. The whistleblower action was filed in March 2000 by Hector Arce, a former employee at the Company's EPREX factory. Mr. Arce contends in the lawsuit that he was pressured to falsify data to cover up manufacturing lapses at the EPREX manufacturing facility, and then was suspended a few days before an expected interview with FDA inspectors. This information, which defendants failed to disclose, was information a reasonable investor would have wanted to know - especially as the reported incidences of PRCA continued to climb during the Class Period - considering EPREX, and its U.S. version, PROCRIT, accounted for over 10% of the Company's revenues in 2001 and was projected to account for 11% of revenues in 2002. The true facts concerning the existence of the criminal investigation of Johnson & Johnson and the allegations of the qui tam action were first revealed in The New York Times on July 19, 2002. That same day, Johnson & Johnson admitted that it was aware of the criminal investigation since April 2002. Once the foregoing information was revealed, Johnson & Johnson shares fell $7.88 per share to close on July 19, 2002, at $41.85, a fall of 16%.

ALZA Corporation 6/22/1999 Securities Breach of Fiduciary Duties: Class Action

No. CV 782725 California

On June 22, 1999, a purported class action lawsuit was filed in the Superior Court of the State of California, County of Santa Clara, against ALZA and all of the current members of its Board of Directors. The action was captioned Lisa Fruchter v. ALZA Corporation, et al., No. CV 782725 (Santa Clara County, California, Superior Court) and alleged that ALZA and its directors breached fiduciary duties owed to ALZA's stockholders when they permitted ALZA to enter into the Merger Agreement with Abbott. In general, the complaint alleged that the exchange ratio under the Merger Agreement was inadequate and further alleged that ALZA's board of directors had an obligation to place ALZA up for auction when it entered into the Merger Agreement. The action sought both an injunction to prevent the merger and damages in the event that the merger is completed. On September 20, 1999 the plaintiffs agreed to dismiss this suit without any liability for ALZA.

Centocor, Inc. 1/16/1998 Securities Securities Class Action 98-CV-00260 Pennsylvania

According to the latest docket posted, on December 13, 1999, the Court entered the Order signed by U.S. District Judge Louis C. Bechtle granting the lead plaintiffs' motion for voluntary dismissal with prejudice pursuant to FRCP 41(a)(2) and 23(e). The consolidated action is dismissed with prejudice and the case closed. As previously reported by the Company's Form 10-Q for the quarterly period ended June 30, 1999, on June 25, 1998, the defendants filed a motion to dismiss the complaint. On December 1, 1998, the Court denied defendants' motion. On December 22, 1998, defendants answered the complaint, denying all liability and raising various affirmative defenses. The Court certified the action as a class action on behalf of all persons who purchased the Company's securities between December 2, 1997 and December 16, 1997. Discovery has been completed. At the conclusion of discovery, plaintiffs' counsel indicated that they would dismiss the action subject to notice to the class and approval by the Court. On August 6, 1999, plaintiffs filed a motion for approval of class notice and to dismiss the action thirty days after notice is given. The original complaint charges Centocor and its chief executive officer with violations of Section 10(b) and 20(a) of the Securities Exchange Act of 1934. According to the complaint, during the Class Period, defendants disseminated numerous announcements concerning the signing of a European marketing partner for Avakine in the fourth quarter of 1997 and its corresponding positive effect on the financial results of the company. Plaintiff alleges that these public statements were materially false and misleading because they failed to disclose that Centocor was not and would not be able to sign a European marketing partner and receive an up-front payment of approximately $27 million in the fourth quarter of 1997 and would not be able to achieve earnings of 50 cents a share for fiscal 1997.

Scios Inc 5/18/1995 Securities Securities Class Action Unknown California


11








On May 18, 1995 a shareholder lawsuit was filed against Scios Nova Inc., The shareholder who purchased the Company's common stock between October 6, 1993 and May 2, 1995. The action alleged violation of the Federal securities laws based on Company statements about clinical studies conducted by the University of Colorado related to AURICULIN(R) anaritide. The suits were filed in the U.S. District Court for the Northern District of California. Also named as a defendant is Richard L. Casey, Chairman and Chief Executive Officer. On September 25, 1996 the securities litigation against Scios Inc. and its Chief executive officer Richard L. Casey, has been dismissed by the United States District Court for the Northern District of California. The dismissal was with prejudice. United States District Judge Marilyn Hall Patel ruled that "Plaintiffs have not pled facts sufficient to explain why defendants' summaries of the Colorado study were false and misleading".

Biosense Webster Inc Employment Discrimination & Harassment: Racial

KC058790 California

Sales VP alleged he was laid off because he's not Israeli In 2002, plaintiff Michael Acevedo, 49, began working for Biosense Webster Inc., a member of the Johnson & Johnson family of companies, which specializes in 3-D mapping technology for the diagnosis and treatment of cardiac arrhythmias. In 2004, Acevedo was promoted to vice president of United States sales for the California/Israel-based company. In 2008, a new president was appointed to the company and headed a project to develop a new generation of cardiac mapping technology. The CARTO 3 System, as it was called, was approved in October 2009 by the Food and Drug Administration. In anticipation of the approval, Biosense planned on merging its sales and clinical services forces. In the interim, due to global financial challenges, Johnson & Johnson mandated that the company reduce staffing. The merger and corresponding layoffs began in November 2009, and included the consolidation of the clinical services and sales vice presidents into one position. Acevedo was one of two candidates considered for the position. Biosense selected the vice president of worldwide services to take the new position of vice president of U.S. sales and worldwide clinical services. Acevedo was laid off as his prior position no longer existed. Acevedo sued Biosense Webster, alleging wrongful termination, national origin discrimination, failure to prevent discrimination and retaliation. Acevedo claimed the clinical services vice president was chosen over him due to his Israeli national origin, and argued the doctrine of disparate impact applied in the case since the defendant "adversely impacted" non-Israeli employees. Acevedo claimed that other Israelis received promotions during the November 2009 merger period, while certain American employees who deserved promotions either didn't get them or were laid off. Biosense contended that Acevedo was not discriminated against in any form, and that he was laid off for legitimate business reasons. It claimed that the new position required a level of technical expertise that Acevedo lacked, and that the other candidate was overall more qualified for the job. Biosense claimed that Acevedo finished second in both the objective and subjective analysis of the decision process. It also claimed that the promotion of any other Israeli employees during the merger was due to their qualifications. Acevedo was able to get a new job for equal pay within three weeks of being laid off. He asked the jury for $1.4 million in lost pension and stock options for Biosense, as well as an unspecified amount in damages for emotional distress. Biosense contended that Acevedo was able to get a new job at a big company that provided its own retirement plan and stock options, and as such, he was owed no economic damages. It further contested plaintiff's claim for emotional distress, arguing that Acevedo didn't even utilize the company's free employee assistance program and he received no psychological counseling for his alleged distress. The jury rendered a defense verdict. The defendant plans on filing a memorandum of costs. 

Ethicon, Inc. Business & Trade Practices


06-21116-CIV Florida

Medical device caused flesh-eating bacteria: plaintiff On Dec. 21, 2001, plaintiff Lana Keeton, 54, a steel broker, had a Gynecare TVT Device inserted into her urethra as part of a surgery at Miami Beach's Mt. Sinai Hospital to relieve incontinence. Keeton claimed to have lost 700 cubic centimeters of blood during the surgery and subsequently suffered a life-threatening infection of flesh-eating bacteria. The TVT System was first marketed in January 1998 with approval from the Federal Food and Drug Administration. Keeton sued Gynecare Worldwide, Ethicon, Inc., and Johnson & Johnson on multiple counts of negligence and strict products liability. Johnson & Johnson owns Ethicon, which operates the division of Gynecare. Keeton alleged that Gynecare Worldwide failed to use reasonable care in the system's design, manufacture and distribution, and failed to train doctors to use the product, as its mesh tape had sharp edges that cause tissue damage. Had she known of these dangers, Keeton said that she would not have consented to the surgery. Keeton, who represented herself, claimed that Gynecare Worldwide failed to test the product on humans prior to its 1998 release, which would have revealed that the TVT System is inherently dangerous and invasive, and thereby committed fraud, fraudulent concealment and misrepresentation. Keeton alleged that Gynecare Worldwide failed to warn of danger in use of the product and failed to design the product in a way that was safe. Gynecare Worldwide, Ethicon, Inc., and Johnson & Johnson denied all allegations of negligence and breach of contract. Counsel argued that the Gynecare TVT Device is only sold to surgeons who are sophisticated users and fully aware of the device's risks and associated characteristics. Gynecare also pointed out that the product complied with the FDA regulations. It has been used on more than 1 million people worldwide. "It has an astounding success rate," defense counsel later said. To testify to the product's efficacy and safety, the defense retained Dr. Steve Goldwasser, a surgeon who has used the device many times. The judge upheld defense counsel's Daubert motion to exclude the findings of the plaintiff's expert, Teeter Schmidt. Keeton claimed that, due to the infection resulting from the Gynecare TVT Device, a large portion of flesh on the left side of her stomach had to be removed. The wound was treated and cleaned by healthcare professionals for two months. Keeton claimed that she was hospitalized for three weeks, bed-ridden for three months and never fully recovered. As a result she lost her business. A portion of the TVT Device cut into and remained inside Keeton's bladder, she said, causing the need for numerous follow-up surgeries. Keeton claimed severe trauma, serious injury, disfigurement, scarring, multiple internal wounds, pain and suffering, loss of enjoyment of life, mental anguish, expense of hospitalization, medical and nursing care and treatment, past and future loss of earnings and loss of earning capacity. The defense contested all of Keeton's claimed injuries and argued that none was substantiated or related to the Gynecare TVT Device. Defense counsel maintained that Keeton's injuries and damages were the result of her underlying medical condition or treatment, but were not caused by any defect in the Gynecare device. Defense counsel contended that Keeton had run into financial problems before and after the surgery. Judge Ursula Ungaro-Benages granted the defense's motion for summary judgment. Lana Keeton has an ongoing lawsuit against her doctor. Lena Keeton, still as a pro se plaintiff, said that she plans to file appeal.

Cordis Corporation Employment Labor Disputes 1:09-cv-20920-CMA Florida

Plaintiffs claimed that they weren't paid for OT hours Plaintiffs Nashoane Fulwood-Kelley, Mabel Fombu and Lissette Pendas worked as complaint handling specialists for Cordis Corp., a developer, manufacturer and distributor of interventional medical devices. The plaintiffs claimed they routinely worked more than 40 hours per week without being compensated at rates equal to one and one half times their regular rates of pay. The plaintiffs sued Cordis Corporation for violation of the overtime provisions of the Fair Labor Standards Act. They claimed the employer engaged in interstate commerce and grossed more than $500,000 annually, as required for applicability of the statute. Cordis claimed the plaintiffs were exempt employees due to their status as administrative employees. The company claimed the position was integral to its operations. The workers exercised discretion and independent judgment with respect to matters of significance, according to the defendant. The plaintiffs sought to collect unpaid overtime wages. Judge Cecilia M. Altonaga granted the defendant's motion for summary judgment.


12

Recent Federal Dockets for the Company

Caption File date Category Docket Number Court

Alwani Kumar v. Johnson & Johnson, Inc et al

2/9/2012 Labor 3:12cv779 US District Court for the District of New Jersey

Napoli v. Johnson & Johnson, Inc

11/4/2011 Labor 3:11cv754 US District Court for the Middle District of Louisiana

Christopher Scruton v. Advanced Sterilization Products Services Inc Et A

8/1/2011 Labor 8:11cv1148 US District Court for the Central District of California

Browne v. Nautilus Insurance Company et al

4/13/2011 Contracts 2:11cv876 US District Court for the District of South Carolina

Bartz v. Ortho McNeil Pharmaceuticals, Inc, et al

2/24/2011 Other 1:11cv10316 US District Court for the District of Massachusetts

Robison v. Johnson & Johnson Inc et al

2/15/2011 Labor 6:11cv15 US District Court for the Northern District of Texas

Rudolph v. McNeil PPC, Inc et al

1/14/2011 Other 1:11cv20150 US District Court for the Southern District of Florida

Bowhall v. Howell High School Board of Education et al (Mag+)

7/14/2010 Torts 2:10cv605 US District Court for the Middle District of Alabama

Degroot v. McNeil Consumer Healthcare et al

7/8/2010 Other 1:10cv4253 US District Court for the Northern District of Illinois

Zhang v. Johnson & Johnson Inc

4/22/2010 Labor 5:10cv1717 US District Court for the Northern District of California

Spindler et al v. Johnson & Johnson Corp et al

4/2/2010 Antitrust 3:10cv1414 US District Court for the Northern District of California

McCloud v. Burger King 1/11/2010 Labor 4:10cv11 US District Court for the Northern District of Florida

Jefferson Pharmacy, Inc v. Abbott Laboratories et al

9/16/2009 Torts 2:09cv81447 US District Court for the Eastern District of Pennsylvania





Clash Events with the Industry

Description Root Cause

IPOs 2001-2002 In Re IPO

Foreign Corrupt Practices Act Civil Suits, follow-ons

Hip & Knee Replacement Products Defective Product


13








Potential Insured Losses based on Industry Experience (Management Liability)

Top Industry Management Liability Cases by Accident/Filing Date


Amount(in millions)

Category Subtype

PRB Pharmaceuticals


Marketing Practices

On June 3, 2011, Charles Hensley, the man who invented Zicam cold remedy was indicted by a federal grand jury for allegedly importing an unapproved he...

Bayer Healthcare Pharmaceuticals Inc.

3/21/2011 Employment Discrimination & Harassment: Gender/Sexual

March 21, 2011, a class action lawsuit was filed in the New Jersey District Court by Plaintiffs Victoria Barghout, Jennifer Christiansen, Barbara Feri...

Senju Pharmaceutical Co.,ltd.


Royalties

On April 29, 2010, Ista Pharmaceuticals Inc filed a complaint against Senju Pharmaceutical Company Ltd in the U.S. District Court for the Central Dist...

Bayer Healthcare Pharmaceuticals Inc.


On March 21, 2011, six former employees Victoria Barghout, Jennifer Christiansen, Barbara Feringa, Jennifer Musumeci, Laura Reilly, and Karen Salomon,...

Merck & Co 9/8/2008 Employment Discrimination & Harassment: Racial

Top Industry Management Liability Cases by Settlement Amount


Amount(in millions)

Category Subtype

Purdue Pharma L.P.


Marketing Practices

On May 10, 2007, Purdue Pharma and three of the company's current and former executives pleaded guilty to misleading the public about the safety of it...

Janssen Pharmaceutica Inc.


Marketing Practices

In 2007, a case was filed by the State of Carolina against Janssen Pharmaceutica, Inc., Janssen, LP, and Johnson & Johnson, Inc. in the 7th Judicial C...

Boehringer Ingelheim GmbH


Billing Fraud

On December 7, 2010, according to a news release, the U.S. Department of Justice announced that Abbott Laboratories Inc. (Abbott), B. Braun Melsungen ...

Purdue Pharma L.P.


Marketing Practices

On September 18, 2007, Purdue Pharma and Purdue Frederick Company (collectively Purdue) agreed to pay to the federal government and 26 state programs ...

King Pharmaceuticals, Inc.


Billing Fraud

On March 23, 2006, Attorney General Jay Nixon for the State of Missouri presented the Missouri Department of Social Services with a check for the stat...

King Pharmaceuticals Inc.


Billing Fraud

Levaquin and Tavanic Litigation Spontaneous tendon ruptures and irreversible peripheral neuropathy

Fentanyl Duragesic Patches Overdose & Death


14








On August 13, 2010, Gordon Goodman, an African American, filed a civil action in the U.S. Eastern District Court of Pennsylvania against Merck & Co In...

Purdue Pharma L.P.

3/1/2008 Cyber/Identity Risks

Unauthorized Data Distribution

Former employee exposes Purdue Pharma personal information: Purdue Pharma recently learned that a former employee accessed a disk containing personal ...

Smithkline Beecham Corporation

1/1/2007 Employment Wage and Hour

On August 14, 2008, Michael Shane Christopher and Frank Buchanan (the Plaintiffs) filed a lawsuit against SmithKline Beecham Corporation d/b/a GlaxoSm...

Oscient Pharmaceuticals Corp

4/28/2006 Employment Wrongful Termination

Firing was based on race, plaintiff alleged Plaintiff Gino Anioce, a black male, worked for Oscient from July 2004 through April 28, 2006, as a terri...

Garden of Life, Inc.


Termination was based on pregnancy, plaintiff alleged: On Nov. 14, 2005, plaintiff Brandi Cooper, 32, a public relations manager for Garden of Life, I...

Ferring BV 2/17/2005 $16.75 Management & Strategy

Anti-trust

On February 18, 2005, a complaint was filed by Meijer, Inc. (Meijer) and several other companies against Ferring B.V. (Ferring) and Aventis Pharmaceut...

'Best Price' Reporting Failures Alleged Against Pharma: This is a False Claims Act case from 1997 until his firing in 2002, relator Ed Bogart, 40s, w...

Mylan Laboratories

1/1/1998 $100.00 Management & Strategy

Anti-trust

33 States, FTC Settle Antitrust Suit with Drug Maker over Alleged Massive Price Hikes: A multistate suit against a Pennsylvania drug manufacturer accu...

Bayer Healthcare LLC


Bribery

Between 1998 and 2002, Bayer HealthCare LLC (Bayer) allegedly paid Liberty Medical Supply Inc., one of the largest direct-to-patient diabetic supplier...

Aventis Pharmaceuticals Inc


Billing Fraud

On May 28, 2009, Aventis Pharmaceutical Inc. (Aventis or Defendant), has agreed to pay the United States $95.5 million to settle allegations that it v...

Aventis Pharmaceuticals Inc

1/24/2003 $80.00 Management & Strategy

Anti-trust

Drug makers conspired to keep generic version off market: In a multi-district litigation, the 50 states, Puerto Rico, and Washington D.C. sued Aventis...

Board and Management Interlocks

Director/Officer Position Interlocked Company Position with Interlocked Company

William C. Weldon Chairman of the Board JPMorgan Chase & Co. Independent Director

Alex Gorsky Chairman - Executive Committee, Chief Executive Officer

Novartis Corp. Chief Executive Officer

David Satcher Independent Director MetLife, Inc. Independent Director

Key Personnel

Name Age Title Officer Since

Alex Gorsky 51 Chairman 2009

Mr. Alex Gorsky became Worldwide Chairman, Medical Devices and Diagnostics Group in September 2009. He served as a Member of the Executive Committee and Worldwide Chairman, Surgical Care Group of Johnson & Johnson in January 2009. He joined Johnson & Johnson in 2008 as Company Group Chairman and Worldwide Franchise Chairman for Ethicon, Inc. Previously, he was head of the North American pharmaceuticals business at Novartis Pharmaceuticals Corporation from 2004 to 2008. Prior to Novartis, Mr. Gorsky served in various management positions at Johnson & Johnson, including Company Group Chairman for the Company's pharmaceutical business in Europe, Middle East and Africa and President of Janssen Pharmaceutica Inc. (U.S.).

Dominic J. Caruso 54 Chief Financial Officer 2007

Mr. Dominic J. Caruso serves as Vice President, Finance and Chief Financial Officer of Johnson & Johnson. He joined Johnson & Johnson in 1999 when the Company acquired Centocor, Inc. At the time of that acquisition, he had been Senior Vice President, Finance of Centocor. Mr. Caruso was named Vice President, Finance of Ortho-McNeil Pharmaceutical, Inc. in 2001 and Vice President, Group Finance of the Company's Medical Devices and Diagnostics Group in 2003. In 2005, Mr. Caruso was named Vice President of the Company's Group Finance organization. Mr. Caruso became a Member of the Executive Committee and was appointed to his current position in 2007.

Michael H. Ullmann 53 General Counsel 2012

Mr. Michael H. Ullmann is the Vice President, General Counsel, Member - Executive Committee of Johnson & Johnson. He Joined the Company in 1989 as a corporate attorney in the Law Department. He was appointed Corporate Secretary in 1999 and served in that role until 2006. During that time, he also held various management positions in the Law Department. In 2006, he was named General Counsel of the Medical Devices and Diagnostics Group. Mr. Ullmann was appointed Vice President, General Counsel and a Member of the Executive Committee in January 2012.

Peter M. Fasolo N/A Director, Human Resources 2010

Peter M. Fasolo joined KKR as Chief Talent Officer in 2008. Mr. Fasolo works during both due diligence and post acquisition phases to help build the management depth and diversity of the KKR North American portfolio companies. His focus is on executive assessment, selection, succession and compensation across the various industry groups for KKR. Mr. Fasolo has over 15 years experience in consulting and working directly in the healthcare and consumer industries. He spent 13 years with Bristol-Myers Squibb in senior level HR Executive roles in the Pharmaceutical, Medical Devices and Consumer segments based in New York City, Ft. Wayne, Indiana, Paris, France and Princeton, New Jersey. Mr. Fasolo joined Johnson & Johnson in 2004 where he worked extensively on the merger and acquisition strategy for the Cordis cardiovascular business. His last position at Johnson & Johnson was Chief Talent Officer. Mr. Fasolo earned a Ph.D. from the University of Delaware, an M.A. from Fairleigh Dickinson University and a B.A. from Providence College. Mr. Fasolo has lectured and written extensively in the area of workplace fairness, leadership, and workforce metrics.


15








Significant Developments - Past 3 Months

Development Date

Johnson & Johnson's Janssen Research & Development, LLC Announces XARELTO (rivaroxaban) Demonstrates Comparable Efficacy To Standard of Care For Treatment & Secondary Prevention Of Venous Blood Clots

03/26/2012

Johnson & Johnson Set To Win EU Okay To Buy Synthes Inc.-Reuters 03/15/2012

U.S. Nixes Tentative $1 Billion Settlement With Johnson & Johnson-Reuters 03/10/2012

Michael M. Johns Independent Director Genuine Parts Company Independent Director

James G. Cullen Presiding Independent Director Agilent Technologies Incorporated Independent Non-Executive Chairman of the Board

James G. Cullen Presiding Independent Director NeuStar, Inc. Independent Chairman of the Board

James G. Cullen Presiding Independent Director Prudential Financial, Inc. Lead Independent Director

Mary S. Coleman Independent Director Meredith Corporation Independent Director

Anne M. Mulcahy Independent Director Target Corporation Independent Director

Anne M. Mulcahy Independent Director The Washington Post Company Independent Director

Peter M. Fasolo Vice President - Global Human Resources, Member - Executive Committee

Kohlberg Kravis Roberts & Co. L.P. Chief


16








17

For more information contact your Advisen rep at +1.212.897.4800, email [email protected] , or visit www.advisen.com

Recent News

Johnson & Johnson's Janssen Research & Development, LLC Announces XARELTO (rivaroxaban) Demonstrates C omparable Efficacy To Standard of Care For Treatment & Second ary Prevention Of Venous Blood Clots

03/26/2012

Johnson & Johnson's Janssen Research & Development, LLC announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO (rivaroxaban) was comparable to standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE). The study also found rivaroxaban had a similar safety profile and significantly lower risk of major bleeding versus the current standard regimen. These data were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Sessions, and published in the New England Journal of Medicine. The EINSTEIN-PE study compared rivaroxaban to enoxaparin followed by vitamin K antagonist (VKA) in the treatment of 4,833 patients with acute symptomatic PE for the prevention of recurrent VTE. Patients received treatment for three, six or 12 months. The Company plans to file the EINSTEIN studies in a supplemental New Drug Application with the Food and Drug Administration during the second quarter of this year. Johnson & Johnson Set To Win EU Okay To Buy Synthes Inc.-Reuters 03/15/2012

Reuters reported that Johnson & Johnson is set to gain EU approval for its planned $21.3 billion buy of Swiss medical devices maker Synthes Inc. after offering concessions to address concerns over its dominance in trauma devices. The EU executive, which is scheduled to decide by April 26 whether to approve the takeover, could issue a decision earlier than that deadline. U.S. Nixes Tentative $1 Billion Settlement With Joh nson & Johnson-Reuters 03/10/2012

Reuters reported that Federal prosecutors in Washington, D.C. have nixed a tentative $1 billion settlement with Johnson & Johnson, holding out for a settlement with the drugmaker for alleged improper marketing of its Risperdal schizophrenia drug, the Wall Street Journal reported. Department of Justice prosecutors in Washington rejected a proposed settlement worked out about two months ago between the Company and federal prosecutors in Philadelphia, and that the deal must now be renegotiated. Officials in the Justice Department's criminal division could not be reached immediately for comment. The Department of Justice for years has been investigating the diversified healthcare company for alleged marketing of the anti-psychotic drug for unapproved uses, including for nursing home residents. Individual states are also pressing similar allegations against the Company. Alex Gorsky To Succeed Bill Weldon As CEO Of Johnso n & Johnson 02/21/2012

Johnson & Johnson announced that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective April 26, 2012, the date of the Company's Annual Meeting of Shareholders. Mr. Gorsky was also nominated for election to the Board of Directors at the Annual Meeting. Mr. Gorsky, 51, currently Vice Chairman of the Company's Executive Committee with responsibility for the Medical Devices & Diagnostics Group, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy, succeeds Bill Weldon, who has served as Chairman and CEO of Johnson & Johnson since 2002. Mr. Weldon remains Chairman of the Board of Directors. FDA Says Ulcer Drugs Such As AstraZeneca PLC's Nexi um May Raise Diarrhea Risk; Other Proton Pump Inhib itors Includes Johnson & Johnson and Eisai Co Ltd's AcipHex-Reuter s

02/08/2012

Reuters reported that U.S. health regulators said ulcer drugs such as AstraZeneca PLC's blockbuster Nexium could increase the risk of clostridium difficile-associated diarrhea (CDAD). Clostridium difficile is a bacteria naturally present in the gut and can cause colitis and other intestinal conditions. The U.S. Food and Drug Administration said patients who develop diarrhea after taking these drugs should be checked for CDAD. The drugs called proton pump inhibitors (PPIs) are widely used for treating ulcers, acid reflux and other conditions. Other PPIs sold by prescription include Takeda Pharmaceutical Co Ltd's Dexilant and Prevacid, AstraZeneca's Prilosec and Vimovo, Santarus Inc's Zegerid, and Johnson & Johnson and Eisai Co Ltd's AcipHex. Generic versions of Prevacid and Prilosec also are available.

Johnson & Johnson Issues FY 2012 EPS Guidance Below Analysts' Estimates 01/24/2012

Johnson & Johnson announced earnings guidance for fiscal 2012 of $5.05 to $5.15 per share (EPS), which excludes the impact of special items. This guidance reflects operational growth of approximately 3.5% to 5.5% partially offset by an estimated negative impact of currency of approximately 2.5%. According to I/B/E/S Estimates, analysts were expecting the Company to report EPS of $5.21 for fiscal 2012.

Federal Court Rules In Favor Of Boston Scientific C orp. in Johnson & Johnson Patent-DJ 01/23/2012

Dow Jones reported that a federal court ruled a stent system made by Boston Scientific Corp. doesn't infringe on Johnson & Johnson patents, a judgment that helps the medical-device maker notch a win in a patent war with the health-care products giant. Johnson & Johnson had alleged in a 2008 suit that Boston Scientific's Promus everolimus-eluting coronary stent system infringed on two of its patents. The two companies have been locked in a long-running battle over intellectual property for heart stents, with both scoring some victories along the way.

Johnson & Johnson To Pay $158 Million To Settle Tex as Risperdal Case-Reuters 01/20/2012

Reuters reported that Johnson & Johnson will pay $158 million to settle a Texas lawsuit accusing the drugmaker of improperly marketing its Risperdal anti-psychotic drug to state residents on the Medicaid health program for the poor, including children. The lawsuit against the company alleged that J&J was pushing Risperdal as 'appropriate and safe to treat a broad range of symptoms in populations and disease states for which it had no FDA approved indication, including in the child and adolescent population'. The settlement fully resolves all Risperdal-related claims in Texas. The agreement is specific to the state of Texas and does not involve other ongoing state or federal Risperdal litigation. The deal settles claims brought by Texas in 2004 and involves alleged Medicaid overpayments during 1994 to 2008 and will circumvent potentially lengthy and costly appellate activities, according to a statement from J&J's Janssen Pharmaceuticals unit.

18


FDA Warns Johnson & Johnson's DePuy Unit Over Joint Replacements-Reuters 01/18/2012

Reuters reported that U.S. health regulators have warned Johnson & Johnson's DePuy Orthopaedics Inc unit against selling joint replacement products without proper approval, prompting the company to stop making some devices. A Food and Drug Administration warning letter to DePuy dated Dec. 8, 2011, said an on-site federal investigation showed the company was selling 14 products without proper approval from DePuy's facilities in Warsaw, Indiana

Johnson & Johnson's Biosense Webster Announces FDA Approval Of THERMOCOOL SF Catheter In The United St ates 01/12/2012

Johnson & Johnson's Biosense Webster, Inc. announced the FDA approval of the new THERMOCOOL SF irrigated ablation catheter in the United States. The THERMOCOOL SF NAV Catheter combines Biosense WebsteraCOs latest irrigated ablation technology with the accurate visualization of the CARTO3 3D Mapping & Ablation System. The catheter was launched in Europe in October, 2010. The THERMOCOOL SF NAV Catheter is approved in the United States for treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with CARTO Systems and Type 1 Atrial Flutter for patients 18 years and older.

19


Web References

Alex Gorsky

Current Position:

Worldwide Chairman, The Surgical Care Group, Manchester, United States Global Chairman, The Surgical Care Group, Manchester, United States

Employment History

Chief Operating Officer , Novartis AG, East Hanover, United States

Chief Executive Officer , Novartis AG, East Hanover, United States

Head of Pharma North America and Chief Executive Of ficer , Novartis AG, East Hanover, United States

President , Janssen L.P, Titusville, United States

Sales Representative , Janssen L.P, Titusville, United States

Chairman , Company Group

Worldwide Chairman , Medical Devices

Head of Pharmaceuticals , J&J

Chief Executive Officer , J&J

Chairman , Worldwide, United States

Education

Bachelor of Science degree , U.S. Military Academy at West Point , N.Y.

Master , Business Administration , The Wharton School of the University of Pennsylvania

Bachelor's of Science degree , U.S. Military Academy

Web Reference

1. InHealth - Board of Directors http://www.inhealth.org/board Published on: 2012-03-21 Alex Gorsky Vice Chairman of the Executive Committee, Johnson & Johnson

2. http://www.pmlive.com/find_an_article/allarticles/categories/people/2012/pharma_appointments_march_2012 Published on: 2012-03-01 Mover of the month is Alex Gorsky, who has become chief executive of Johnson & Johnson | PMLiVE"/> Mover of the month is Alex Gorsky, who has become chief executive of Johnson & Johnson " /> Contact us Alex Gorsky, J&J Johnson & Johnson (J&J) has selected Alex Gorsky to succeed long-serving chief executive William Weldon at its annual meeting in April 2012. Gorsky (51) is currently vice chairman of J&J's executive committee and will take over from Weldon, the chairman and CEO since 2002, on April 26. Gorsky started working for J&J in 1988 as a sales representative for the firm's Janssen Pharmaceutica subsidiary, rising to the position of president of Janssen in 2001 and then chairman of the group's Europe, Middle East and Africa pharmaceuticals business in 2003. He had a four-year stint at Novartis between 2004 and 2008, before returning to head J&J's Ethicon medical device business.

3. http://www.philly.com/philly/business/20120226_Alex_Gorsky_takes_on_consumer_trust_.html Published on: 2012-02-26 Alex Gorsky takes on consumer trust Alex Gorsky is shown here. Johnson & Johnson´s longtime CEO, Bill Weldon, is retiring in April, following an embarrassing string of product recalls over more than two years that has cost the health care giant hundreds of millions of dollars and consumer trust. (AP Photo/Johnson &

20


Johnson) Alex Gorsky is shown here. Alex Gorsky got a promotion Tuesday, but the challenge confronting the next chief executive officer of Johnson & Johnson is visible in some of the other jobs that still need filling at the global health-care company's facility in Fort Washington, home to some of its most iconic brands. Gorsky, who started as a Janssen sales rep, was leading the company in the early 2000s when problems with the drug first came to light. Gorsky got the job in part because he was in charge of J&J's DePuy medical-device unit and was intimately involved in J&J's pending $21.3 billion acquisition of Synthes Inc., another device-maker, with several facilities in Chester County. Before J&J made the largest purchase in its history, Gorsky met several times with Synthes chairman Hansjorg Wyss in 2010 when Wyss was looking to sell his company. Gorsky holds an M.B.A. from Wharton.

4. http://biz.thestar.com.my/news/story.asp?file=/2012/2/22/business/20120222133945&sec=business Published on: 2012-02-22 Vice Chairman Alex Gorsky, 51, will become CEO effective April 26, the date of J&J's next board meeting, the company said. Gorsky was also nominated to the board, it added. Gorsky is the latest in a long line of CEOs to come from within the company, although he left in 2004 for a four-year stint as Novartis' head pharmaceuticals in North America before returning to J&J. Gorsky began his J&J career in 1988 as a sales representative with the Janssen Pharmaceutica unit. In 2001, he was appointed President of Janssen, and in 2003, Gorsky became Company Group Chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. After returning to the J&J fold he became global chairman of the Surgical Care Group. "It is a testament to the leadership development and succession planning process at Johnson & Johnson that Mr. Gorsky, like all of the previous chief executives in the company's 126-year history, was appointed from within the organization," Jim Cullen, a member of the board of directors, said in a statement.

5. http://www.drugstorenews.com/article/jj-names-successor-ceo?ad=front-end-categories Published on: 2012-02-22 Alex Gorsky will assume role at shareholders meeting J&J's Alex Gorsky, Sheri McCoy named vice chairmen NEW BRUNSWICK, N.J. - Johnson & Johnson on Tuesday named Alex Gorsky CEO of the company, effective April 26, the date of the company's annual meeting of shareholders. Gorsky also has been nominated for election to the board of directors at the meeting. Gorsky, 51, currently vice chairman of the company's executive committee with responsibility for the medical devices and diagnostics group, global supply chain, healthcare compliance, and privacy and government affairs and policy, succeeds Bill Weldon, who has served as chairman and CEO of Johnson & Johnson since 2002. As CEO, Gorsky will assume full management responsibilities for Johnson & Johnson, including those currently reporting to him and to Weldon. Jim Cullen, the independent presiding director of the Board of Directors, added: "It is a testament to the leadership development and succession planning process at Johnson & Johnson that Mr. Gorsky, like all of the previous chief executives in the Company's 126-year history, was appointed from within the organization." Gorsky began his Johnson & Johnson career in 1988 as a sales representative with Janssen Pharmaceutica. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management. In 2001, he was appointed president of Janssen, and in 2003, promoted to company group chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. He left the company in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company's pharmaceuticals business in North America. Four years later, he returned to Johnson & Johnson as company group chairman and worldwide franchise chairman for Ethicon in the medical devices business. In 2009, he was appointed worldwide chairman of the surgical care group and to the Johnson & Johnson executive committee. He was appointed vice chairman of the executive committee in January 2011. Gorsky holds a Bachelor of Science degree from the U.S. Military Academy at West Point, and spent six years in the U.S. Army. In 1996, he earned a Master of Business Administration degree from the Wharton School of the University of Pennsylvania. Alex Gorsky

6. http://consumergoods.edgl.com/news/Johnson---Johnson-Names-New-CEO78741 Published on: 2012-02-22 Johnson & Johnson announces that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective April 26, 2012, the date of the company's Annual Meeting of Shareholders. Gorsky was also nominated for election to the Board of Directors at the Annual Meeting. Gorsky is currently Vice Chairman of the company's Executive Committee with responsibility for the Medical Devices & Diagnostics Group, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy, succeeds Bill Weldon, who has served as Chairman and CEO of Johnson & Johnson since 2002. As CEO, Gorsky will assume full management responsibilities for Johnson & Johnson, including those currently reporting to him and to Weldon. Gorsky will succeed Weldon as Chairman of the company's Executive Committee on April 26. Weldon will relinquish his role on the Executive Committee at that time and work with Gorsky in the interim to ensure a seamless transition of leadership. Gorsky began his Johnson & Johnson career in 1988 as a sales representative with Janssen Pharmaceutica in the Pharmaceuticals business. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, he was appointed President of Janssen, and in 2003, promoted to Company Group Chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. He left the Company in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company's pharmaceuticals business in North America. Four years later, he returned to Johnson & Johnson as Company Group Chairman and Worldwide Franchise Chairman for Ethicon in the medical devices business. In 2009, he was appointed Worldwide Chairman of the Surgical Care Group and to the Johnson & Johnson Executive Committee. He was appointed Vice Chairman of the Executive Committee in January 2011.

7. http://www.ivpressonline.com/sns-rt-us-johnsonjohnsontre81k1yo-20120221,0,7037690.story Published on: 2012-02-21 Vice Chairman Alex Gorsky, 51, will become CEO at the next board meeting on April 26, making him the ninth person to lead the company since J&J's founding in 1886. "Gorsky is inheriting a company with a better pharmaceutical pipeline than it had 5 or 6 years ago," Morgan, Keegan & Co analyst Jan Wald said. Gorsky is the latest in a long line of CEOs to come from within the company, although he left in 2004 for a four-year stint as Novartis' head of pharmaceuticals in North America before returning to J&J. Gorsky began his J&J career in 1988 as a sales representative with the Janssen Pharmaceutica unit. In 2001, he was appointed president of Janssen, and in 2003, Gorsky became group chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. After returning to

21


the J&J fold he became global chairman of the Surgical Care Group. Investors had expected Weldon would be succeeded by Gorsky or co-Vice Chairman Sheri McCoy, who were promoted to the shared post in December 2010. McCoy will report to Gorsky and continue to lead the company's pharmaceuticals and consumer groups. "Medical devices has now become their biggest division by sales and earnings and is going to be even bigger when the Synthes deal closes, and that's obviously Alex Gorsky's background," said Jeff Jonas, co-portfolio manager for the Gabelli Healthcare and Wellness Trust, which holds J&J stock.

8. http://www.prnewswire.com/news-releases/alex-gorsky-to-succeed-bill-weldon-as-ceo-of-johnson--johnson-139889553.html Published on: 2012-02-21 Alex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson Alex Gorsky to Succeed Bill Weldon as CEO of Johnson &... -- NEW BRUNSWICK, N.J., Feb. 21, 2012 /PRNewswire-FirstCall/ -- PR Newswire: news distribution, targeting and monitoring See more news releases in: Household, Consumer & Cosmetics, Health Care & Hospitals, Personnel Announcements Click to view news release full screen Alex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson NEW BRUNSWICK, N.J., Feb. 21, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective April 26, 2012, the date of the Company's Annual Meeting of Shareholders. Mr. Gorsky was also nominated for election to the Board of Directors at the Annual Meeting. (Photo: http://photos.prnewswire.com/prnh/20120221/NY57240-a ) (Photo: http://photos.prnewswire.com/prnh/20120221/NY57240-b ) Mr. Gorsky, 51, currently Vice Chairman of the Company's Executive Committee with responsibility for the Medical Devices & Diagnostics Group, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy, succeeds Bill Weldon, who has served as Chairman and CEO of Johnson & Johnson since 2002. Mr. Weldon remains Chairman of the Board of Directors. Jim Cullen, the independent presiding director of the Board of Directors, said: "It is a testament to the leadership development and succession planning process at Johnson & Johnson that Mr. Gorsky, like all of the previous chief executives in the company's 126-year history, was appointed from within the organization." Mr. Gorsky will succeed Mr. Weldon, 63, as Chairman of the Company's Executive Committee on April 26. Mr. Weldon will relinquish his role on the Executive Committee at that time and work with Mr. Gorsky in the interim to ensure a seamless transition of leadership. "Our success at developing outstanding leaders from within is reflected in the selection of Alex to lead our great company forward," Mr. Weldon said. "Alex and Sheri are two extraordinary leaders. Mr. Gorsky began his Johnson & Johnson career in 1988 as a sales representative with Janssen Pharmaceutica in the Pharmaceuticals business. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, he was appointed President of Janssen, and in 2003, promoted to Company Group Chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. He left the Company in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company's pharmaceuticals business in North America. Four years later, he returned to Johnson & Johnson as Company Group Chairman and Worldwide Franchise Chairman for Ethicon in the medical devices business. In 2009, he was appointed Worldwide Chairman of the Surgical Care Group and to the Johnson & Johnson Executive Committee. He was appointed Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky holds a Bachelor of Science degree from the U.S. Military Academy at West Point, NY, and spent six years in the U.S. Army. In 1996, he earned a Master of Business Administration (MBA) degree from the Wharton School of the University of Pennsylvania.

9. http://www.fiercemedicaldevices.com/press-releases/alex-gorsky-succeed-bill-weldon-ceo-johnson-johnson Published on: 2012-02-21 Alex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson Alex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson New Brunswick, NJ (Feb. 21, 2012) - Johnson & Johnson today announced that its Board of Directors has named Alex Gorsky Chief Executive Officer (CEO) of Johnson & Johnson effective April 26, 2012, the date of the Company's Annual Meeting of Shareholders. Mr. Gorsky was also nominated for election to the Board of Directors at the Annual Meeting. Mr. Gorsky, 51, currently Vice Chairman of the Company's Executive Committee with responsibility for the Medical Devices & Diagnostics Group, Global Supply Chain, Health Care Compliance & Privacy and Government Affairs & Policy, succeeds Bill Weldon, who has served as Chairman and CEO of Johnson & Johnson since 2002. As CEO, Mr. Gorsky will assume full management responsibilities for Johnson & Johnson, including those currently reporting to him and to Mr. Weldon. Jim Cullen, the independent presiding director of the Board of Directors, said: "It is a testament to the leadership development and succession planning process at Johnson & Johnson that Mr. Gorsky, like all of the previous chief executives in the Company's 126-year history, was appointed from within the organization." Mr. Gorsky will succeed Mr. Weldon, 63, as Chairman of the Company's Executive Committee on April 26. Mr. Weldon will relinquish his role on the Executive Committee at that time and work with Mr. Gorsky in the interim to ensure a seamless transition of leadership. "Our success at developing outstanding leaders from within is reflected in the selection of Alex to lead our great company forward," Mr. Weldon said. "Alex and Sheri are two extraordinary leaders. Mr. Gorsky began his Johnson & Johnson career in 1988 as a sales representative with Janssen Pharmaceutica in the Pharmaceuticals business. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, he was appointed President of Janssen, and in 2003, promoted to Company Group Chairman of Johnson & Johnson's pharmaceuticals business in Europe, the Middle East and Africa. He left the Company in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company's pharmaceuticals business in North America. Four years later, he returned to Johnson & Johnson as Company Group Chairman and Worldwide Franchise Chairman for Ethicon in the medical devices business. In 2009, he was appointed Worldwide Chairman of the Surgical Care Group and to the Johnson & Johnson Executive Committee. He was appointed Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky holds a Bachelor of Science degree from the U.S. Military Academy at West Point, NY, and spent six years in the U.S. Army. In 1996, he earned a Master of Business Administration (MBA) degree from the Wharton School of the University of Pennsylvania.

10. - Healthcare Businesswomen’s Association About - Advisory Board http://www.hbanet.org/About/Advisory-Board.aspx Published on: 2011-11-17 Alex Gorsky Worldwide Chairman, Medical Devices & Diagnostics Johnson & Johnson

22


James Cullen

Current Position:

Board Member, Prudential, Newark, United States President and Chief Operating Officer, Prudential, Newark, United States

Employment History

Non-Executive Chairman , NeuStar Inc., Sterling, United States

Non-Executive Chairman of Directors , Agilent Technologies Inc., Santa Clara, United States

Member of the Office of Chairman , Agilent Technologies Inc., Santa Clara, United States

Director and Chairman of the Audit Committee , Johnson & Johnson

President and Chief Operating Officer , Bell Atlantic Corporation, New York, United States

Chief Executive Officer, Telecom Group , Bell Atlantic Corporation, New York, United States

Education

B.A. degree , economics , Rutgers University

master's degree , management science , Massachusetts Institute of Technology

Web Reference

1. Johnson & Johnson - Investor Relations - Board o f Directors http://www.investor.jnj.com/governance/bio.cfm Published on: 2012-02-29 James G. Cullen Retired President and Chief Operating Officer, Bell Atlantic Corporation

2. Johnson & Johnson - Investor Relations - Board o f Directors http://www.investor.jnj.com/governance/biodetail.cfm?bioid=3187 Published on: 2012-02-29 James G. Cullen Johnson & Johnson - Investor Relations - Board of Directors Careers Name: James G. Cullen Biography: Mr. Cullen was elected to the Board of Directors in 1995 and is the Presiding Director of the Board, Chairman of the Audit Committee and a member of the Nominating & Corporate Governance Committee. Mr. Cullen retired as President and Chief Operating Officer of Bell Atlantic Corporation (communications) in 2000. He had assumed those positions in 1998, after having been Vice Chairman since 1995 and, prior to that, President since 1993. He was President and Chief Executive Officer of Bell Atlantic-New Jersey, Inc. from 1989 to 1993. He is a Director of Eisenhower Medical Center. With years of demonstrated managerial ability as CEO and COO of a large telecommunications company, and as the current independent, non-executive Chairman of the Board of Directors of Agilent Technologies, Inc. and NeuStar, Inc., Mr. Cullen brings to the Company's Board a wealth of knowledge of organizational and operational management as well as board leadership experience essential to a large public company.

3. http://www.morrisanderson.com/resource-center/entry/Neustar-Class-A-United-States-dips-0.3-on-weak-volume-February-27-2012/ Published on: 2012-02-27 The chairman is James G. Cullen, the chief executive officer is Lisa A. Hook and the chief financial officer is Paul S. Lalljie.

4. AGILENT TECHNOLOGIES INC (A) Latest News â?? Mar ketBrief http://marketbrief.com/a Published on: 2012-02-21 $ 680,700 of Agilent Technologies Inc (A) stock sold by James Cullen; 1 Additional Transaction James Cullen sold 13,638 shares of Agilent Technologies Inc stock, or $680,700 worth, as noted in an SEC Filing today. After the transaction, James Cullen reported their stake in Agilent Technologies ...

23


5. http://phx.corporate-ir.net/phoenix.zhtml?c=189420&p=irol-govcommcomp Published on: 2012-02-03 James G. Cullen Financial Expert Chairperson Committee Member

6. http://phx.corporate-ir.net/phoenix.zhtml?c=189420&p=irol-govboard Published on: 2012-02-03 James G. Cullen Chairman of the Board of Directors

7. http://www.researchbank.co.uk/Prudential-Financial-Inc-Company-Profile.htm Published on: 2012-01-11 James G Cullen, Director

8. Neustar, Inc. – Biography

http://phx.corporate-ir.net/phoenix.zhtml?c=189420&p=irol-govBio&ID=137353 Published on: 2012-01-07 James G. Cullen Neustar, Inc. - Biography James G. Cullen Chairman of the Board of Directors Mr. Cullen has served as a director of Neustar since 2005 and as our Chairman of the Board since 2010. Mr. Cullen retired as President and Chief Operating Officer of Bell Atlantic Corporation, a local telephone exchange carrier, in 2000. He had assumed those positions in 1998, after having been Vice Chairman since 1995 and, prior to that, President since 1993. He was President and Chief Executive Officer of Bell Atlantic-New Jersey, Inc. from 1989 to 1993. Mr. Cullen is also a director, audit committee member and chairman of the compensation committee of Prudential Financial, Inc., non-executive Chairman of the Board of Agilent Technologies, Inc. and a director and chairman of the audit committee of Johnson & Johnson.

9. http://www.prudential.com/view/page/public/15293?src=oc&name=bod#BoardofDirectors Published on: 2011-07-06 James G. Cullen Retired President & Chief Operating Officer Bell Atlantic Corporation Jim Cullen has been a member of the Board of Directors of Prudential Financial, Inc. ("PFI") since 2001 and appointed by the Chief Justice of the New Jersey Supreme Court to the Board of Directors of The Prudential Insurance Company of America ("PICA") in 1994. He has served on the Audit Committee since 2002; has served on the Compensation Committee of PICA since 1994 and the PFI Committee since 2001; became the Chairman of the Compensation Committees of both companies in 2004; and has served on the Executive Committees of both companies since 2004. He also was elected Lead Director of both companies in May 2011 and is the Chair of the Executive Committees. He previously served on the Ethics Committee. Mr. Cullen served as the President and Chief Operating Officer of Bell Atlantic Corporation (a global telecommunications company) from December 1998 until his retirement in June 2000. Mr. Cullen was the President and CEO, Telecom Group, Bell Atlantic Corporation from 1997 to 1998 and served as Vice Chairman of Bell Atlantic Corporation from 1995 to 1997. Mr. Cullen has served as Non-Executive Chairman of the Board of NeuStar, Inc. since November 2010 and the Non-Executive Chairman of the Board of Agilent Technologies, Inc. since March 2005. Mr. Cullen's areas of expertise include business head/administration, business operations, corporate governance, international, marketing/sales and talent management. Mr. Cullen sits on the Boards of Agilent Technologies, Inc., Johnson & Johnson and NeuStar, Inc. James G. Cullen, Retired President and COO, Bell Atlantic Corporation.

10. http://www.sec.gov/Archives/edgar/data/1142630/0001225208-11-014046.txt Published on: 2011-05-12 0001142630 CULLEN JAMES 751 BROAD STREET, 4TH FLOOR ATTN. CORPORATE COMPLIANCE NEWARK NJ 07102 1

Susan Lindquist

Current Position:

Professor of Biology, Massachusetts Institute of Technology, Cambridge, United States

24


Employment History

Member and Director , Johnson & Johnson, New Brunswick, United States

Investigator , Howard Hughes Medical Institute, Ashburn, United States

Albert D. Lasker Professor of Medical Sciences , University of Chicago, Chicago, United States

Biologist , University of Chicago, Chicago, United States

Intellectual-Property Project Manager , University of Chicago, Chicago, United States

Education

doctorate , biology , Harvard University

bachelor's degree , microbiology , University of Illinois

Web Reference

1. Johnson & Johnson - Investor Relations - Board o f Directors http://www.investor.jnj.com/governance/biodetail.cfm?bioid=5191 Published on: 2012-02-29 Susan L. Lindquist, Ph.D. Johnson & Johnson - Investor Relations - Board of Directors Careers Name: Susan L. Lindquist, Ph.D. Biography: Dr. Lindquist was elected to the Board of Directors in 2004 and is a member of the Science & Technology Advisory Committee and the Public Policy Advisory Committee. She is a member of the Whitehead Institute, a non-profit, independent research and educational institution, a Professor of Biology at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute. Dr. Lindquist served as Director of the Whitehead Institute from 2001 to 2004. Previously she was affiliated with the University of Chicago where she was the Albert D. Lasker Professor of Medical Sciences in the Department of Molecular Genetics and Cell Biology. Dr. Lindquist was elected to the American Academy of Arts and Sciences in 1996, the National Academy of Sciences in 1997, the American Philosophical Society in 2003 and the Institute of Medicine in 2006. She received the Novartis/Drew Award for Biomedical Research in 2000, the Dickson Prize in Medicine in 2002, the Sigma Xi William Procter Prize for Academic Achievement in 2006, the Nevada Silver Medal for Scientific Achievement in 2007, the Genetics Society of America Medal and the Centennial Medal of the Harvard University Graduate School of Arts and Sciences in 2008. In 2010, she received the Mendel Medal from the Genetics Society (UK), The DelbrÃ¼ck Medal from Bayer Schering, and the National Medal of Science (USA). She is a member of the Scientific Advisory Boards of the Stowers Institute for Medical Research and the Institut fÃ¼r Molekulare Biotechnologie GmbH. She is also a Co-Founder of FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc. From her long and decorated career in scientific research and her global reputation as a pioneer in biomedical innovation, Dr. Lindquist brings to the Company's Board an incomparable perspective on the intersection of academic and commercial medical research critical to a company in the health care industry.

2. Johnson & Johnson - Investor Relations - Board of D irectors http://www.investor.jnj.com/textonly/governance/bio.cfm Published on: 2012-02-29 Susan L. Lindquist, Ph.D. Member and Former Director, Whitehead Institute for Biomedical Research; Professor of Biology, Massachusetts Institute of Technology

3. 2010 Annual Report - Johnson & Johnson http://www.investor.jnj.com/2010annualreport/board/index.html Published on: 2012-02-29 Susan L. Lindquist Susan L. Lindquist, Ph.D. Member and Former Director, Whitehead Institute for Biomedical Research; Professor of Biology, Massachusetts Institute of Technology Susan L. Lindquist, Ph.D. Susan L. Lindquist, Ph.D.

4. http://www.americanscientist.org/science/pub/stem-cell-treatment-reduces-scar-tissue-after-heart-attack Published on: 2012-02-20 Susan Lindquist suspected that blocking a protein called Hsp90 could thwart cancer. The intellectual-property project manager at the University of Chicago she met with disagreed, calling Lindquist's idea "ridiculous" because it stemmed from experiments in yeast. Today, more than a dozen drug companies are developing inhibitors of the protein as cancer treatments.

25


5. Scientific advisory board | Moleclues 2.0 http://www.moleclues.org/scientific-advisory-board Published on: 2012-01-30 Susan Lindquist Whitehead Institute for Biomedical Research, MIT, United States

6. Biological Psychology Links http://www.biopsychology.com/news/index.php?descType=always&id=16&type=chapter&page=0 Published on: 2012-01-28 Bijal P. Trivedi On a frigid winter's morning in 1992, Susan Lindquist, then a biologist at the University of Chicago in Illinois, trudged through the snow to the campus's intellectual-property office to share an unconventional idea for a cancer drug. A protein that she had been working on, Hsp90, guides misfolded proteins into their proper conformation. But it also applies its talents to misfolded mutant proteins in tumour cells, activating them and helping cancer to advance. Lindquist suspected that blocking Hsp90 would thwart the disease. The intellectual-property project manager she met with disagreed, calling Lindquist's idea â??ridiculousâ? because it stemmed from experiments in yeast. His â??sneering toneâ?, she says, left an indelible mark. â??It was actually one of the most insulting conversations I've had in my professional life.â? It led her to abandon her cancer research on Hsp90 for a decade. Today, more than a dozen drug companies are developing inhibitors of the protein as cancer treatments. Lindquist seems able to shrug off such injustices, now. Her work over the past 20 years has consistently challenged standard thinking on evolution, inheritance and the humble yeast. She has helped to show how misfolded infectious proteins called prions can override the rules of inheritance in yeast, and how this can be used to model human disease. She has also proposed a mechanism by which organisms can unleash hidden variation and evolve by leaps and bounds. She was the first female director of the prestigious Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, and has received more than a dozen awards and honours in the past five years.

7. Keynote Lectures Detailed Information http://2011.the-embo-meeting.org/programme/keynotes/89.html Published on: 2012-01-03 Susan Lindquist | Louis-Jeantet Prize Lectures: May-Britt Moser & Stefan Jentsch | Richard Axel Susan Lindquist MIT, US Susan Lindquist is a member and former Director of the Whitehead Institute for Biomedical Research, which she guided as the Whitehead Genome Center was transformed into the neighbouring Broad Institute. She is also a Howard Hughes Medical Institute Investigator and Professor of Biology at Massachusetts Institute of Technology, US. She received her Ph.D. in biology from Harvard and was a postdoctoral fellow of the American Cancer Society. She was named the Albert D. Lasker Professor of Medical Sciences in 1999 at the University of Chicago. A pioneer in the study of protein folding, she established that protein homeostasis has profound and completely unexpected effects on normal biology and disease. She found that the chaperone Hsp90 potentiates and buffers the effects of genetic variation, fuelling evolutionary mechanisms as diverse as malignant transformation and the emergence of drug resistance. Her work established the molecular basis for protein-based mechanisms of inheritance. More recently she has built tractable genetic models of complex protein misfolding diseases, including Parkinson's and Huntington's diseases, which are providing new insights on the underlying pathogenic mechanisms. Dr. Lindquist is an elected member of the National Academy of Sciences and the Institute of Medicine. Her honours also include the Dickson Prize in Medicine, Sigma Xi William Procter Prize for Scientific Achievement, Centennial Medal of the Harvard University Graduate School of Arts and Sciences, Otto-Warburg Prize, Genetics Society of America Medal, and FASEB Excellence in Science Award.

8. http://2011.the-embo-meeting.org/mediacentre/advisories.html Published on: 2012-01-03 Susan Lindquist, 2010 winner of the US National Medal of Science - Lamarck redux: Prions, Hsp90 and the inheritance of environmentally acquired trait David Anderson, Richard Axel, Cori Bargmann, Bonnie Bassler, Jeffrey Bennetzen, Simon Boulton, Evan Eichler, Florian Engert, B. Brett Finlay, Stefan Jentsch, Susan Lindquist, Edvard Moser, May- Britt Moser, Mark Pagel, Paul Rainey, Giacomo Rizzolati, Paul Schulze-Lefert, Lucy Shapiro and Michael Stratton are some of the leading researchers at the conference who will present in keynote, plenary and special lectures. Susan Lindquist and Giacomo Rizzolatti to speak at The EMBO Meeting 2011 Two Meet the Press events: Susan Lindquist and Giacomo Rizzolatti

9. http://www.sec.gov/Archives/edgar/data/1276829/0000200406-11-000126.txt Published on: 2011-12-15 0001276829 LINDQUIST SUSAN L JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 1 0 0 0

26


10. Molecular Frontiers - Scientific Advisory Board http://www.molecularfrontiers.org/pages/people/scientificadvisoryboard.php Published on: 2011-12-05 Susan Lindquist, Ph.D. Whitehead Institute for Biomedical Research, MIT, United States

Michael Johns

Current Position:

University Chancellor, Emory University, Atlanta, United States Chancellor, Emory University, Atlanta, United States Executive Vice President for Health Affairs Emory University, Atlanta, United States

Employment History

Chairman , Genuine Parts Co, Atlanta, United States

Dean, Genuine Parts Co, Atlanta, United States

Chairman , EHCA Inc, Erie, United States

Vice Chair of the Council , Institute of Medicine, Washington Dc, United States

Vice President of the Medical Faculty , Johns Hopkins University, Baltimore, United States

Vice President for Medical Affairs , Johns Hopkins University, Baltimore, United States

Dean, Johns Hopkins University, Baltimore, United States

Executive Vice President for Health Affairs and Chi ef Executive Officer , Robert W. Woodruff Health Sciences Center of Emory University, Atlanta, United

States

Chief Executive Officer , Robert W. Woodruff Health Sciences Center

Executive Vice President for Health Affairs and Chi ef Executive Officer , Robert W. Woodruff Health Sciences Center

Executive Vice President for Health Affairs and Dir ector , Robert W. Woodruff Health Sciences Center

Chief Executive Officer , Woodruff Health Sciences Center

Executive Vice President for Health Affairs and Dir ector , Woodruff Health Sciences Center

Education

bachelor's degree , Wayne State University

University of Michigan Medical School

Web Reference

1. Johnson & Johnson - Investor Relations - Board o f Directors http://www.investor.jnj.com/governance/bio.cfm Published on: 2012-02-29 Michael M.E. Johns, M.D. Chancellor, Emory University

2. Johnson & Johnson - Investor Relations - Board o f Directors http://www.investor.jnj.com/textonly/governance/biodetail.cfm?bioid=3192 Published on: 2012-02-29

27


Michael M.E. Johns, M.D. | Text Only Johnson & Johnson - Investor Relations - Board of Directors Name: Michael M.E. Johns,, M.D. Biography: Dr. Johns was elected to the Board of Directors in 2005 and is a member of the Compensation & Benefits Committee and the Science & Technology Advisory Committee. He has served since October 2007 as Chancellor of Emory University. From 1996 to 2007, Dr. Johns served as Executive Vice President for Health Affairs and Chief Executive Officer of the Robert W. Woodruff Health Sciences Center of Emory University. As the Executive Vice President for Health Affairs, he oversaw Emory University's widespread academic and clinical programs in health sciences and led strategic planning initiatives for both patient care and research. In addition, from 1996 to 2007, he served as the Chairman of the Board of Emory Healthcare, the largest health care system in Georgia. From 1990 to 1996, Dr. Johns served as Dean of the Johns Hopkins School of Medicine and Vice President of the Medical Faculty at Johns Hopkins University. Dr. Johns is Past Chair of the Council of Teaching Hospitals, a fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine. He is a member of the editorial board of the Journal of the American Medical Association (JAMA) and chairs the Publication Committee of the journal Academic Medicine. Having served in numerous senior leadership positions at some of the nation's most prestigious academic institutions, hospitals and health care systems, Dr. Johns provides a valuable combination of experience at the highest levels of both patient care and medical research, as well as organizational management skills and public health policy expertise, making him an integral board member of a company in the health care industry.

3. 2010 Annual Report - Johnson & Johnson http://www.investor.jnj.com/2010annualreport/board/index.html Published on: 2012-02-29 Michael M.E. Johns Michael M.E. Johns, M.D. Chancellor, Emory University

4. AMN Healthcare Investors - Board of Directors http://amnhealthcare.investorroom.com/boardofdirectors Published on: 2012-02-22 Dr. Michael M.E. Johns Chancellor for Emory University

5. AMN Healthcare Investors - Board of Directors http://amnhealthcare.investorroom.com/boardofdirectors?item=7 Published on: 2012-02-22 Dr. Michael M.E. Johns AMN Healthcare Investors - Board of Directors AMN Careers | Healthcare News | Media Room | Education Services | Investors Dr. Michael M.E. Johns Committees: Corporate Governance Committee, Compensation and Stock Plan Committee Chancellor for Emory University Michael M.E. Johns, M.D. has served as a director since December 2008, and serves as a member of the Compensation and Stock Plan and Corporate Governance Committees. Dr. Johns has extensive healthcare experience and is a recognized healthcare thought leader. In addition, Dr. Johns has experience sitting on the Board of a large publicly-traded company, Johnson & Johnson, since 2005, and serving on its Compensation Committee. In October 2007, Dr. Johns was appointed Chancellor of Emory University. From 1996 to 2007, Dr. Johns served as Executive Vice President for Health Affairs and Chief Executive Officer of the Robert W. Woodruff Health Sciences Center of Emory University and the Chairman of the Board of Directors of Emory Healthcare. From 1990 to 1996, Dr. Johns was Dean of the Johns Hopkins School of Medicine and Vice President of the Medical Faculty at Johns Hopkins University. In addition to Johnson & Johnson, Dr. Johns also serves on several boards, including the Genuine Parts Company since 2000, where he serves on the compensation, governance and nominating committee, and the Board of Regents of the Uniformed Services University for the Health Sciences. He also sits on several philanthropic boards, including the National Health Museum Board.

6. AMN Healthcare Investors - Corporate Governance http://amnhealthcare.investorroom.com/boardcommittees Published on: 2012-02-22 Dr. Michael M.E. Johns

7. ACS HPRI - Board http://www.acshpri.org/board.html Published on: 2012-02-17 Michael M.E. Johns, MD (Chairman) Chancellor, Emory University

8. http://translationalhealthscience.com/thought-leaders.html Published on: 2012-02-10 Michael Johns, MD Michael Johns, MD Chancellor, Emory University; Executive Vice President for Health Affairs, Emeritus Michael Johns, MD Before becoming Emory University's fifth chancellor in 2007, Dr. Johns led a comprehensive strategy that positioned the Woodruff Health Sciences Centre as one of the nation's preeminent academic health centres in education, research, and patient care. The research enterprise was reshaped to become more collaborative and

28


interdisciplinary, with funding support for the centre's biomedical and behavioral research more than doubling over 10 years. From 1990 to 1996, Dr. Johns was Dean of the Johns Hopkins School of Medicine. Under his leadership, the medical school moved into first place among all medical schools in sponsored research, completely revamped its curriculum to meet the challenges of a new era in healthcare, and developed a technology transfer program considered a model of its kind.

9. I-Trax Inc., Health Management Solutions http://www.i-trax.com/OurPeople/BoardOfDirectors.asp Published on: 2012-02-01 Michael M.E. Johns, M.D., has been a director of I-trax since February 2001. Dr. Johns was a director of Health Management from October 2000 to February 2001. Since 1996, Dr. Johns has served as an Executive Vice President for Health Affairs of Emory University, overseeing Emory University's widespread academic and clinical programs in health sciences. In this position, Dr. Johns leads strategic planning initiatives for both patient care and research. In addition, since 1996, Dr. Johns has served as the Chairman of the Board of Emory Healthcare, a comprehensive healthcare system in metropolitan Atlanta. Dr. Johns also is Chairman of the Board of EHCA, LLC, a company overseen jointly by Emory Healthcare and HCA Corporation. Through EHCA, Emory is responsible for clinical performance improvement and quality assurance in six local hospitals and five surgery centers owned by HCA Corporation. From 1990 to 1996, Dr. Johns served as the Dean of the Johns Hopkins School of Medicine and Vice President of the Medical Faculty at Johns Hopkins University

10. http://www.sec.gov/Archives/edgar/data/40987/0001209191-12-002592.txt Published on: 2012-01-06 0001221096 JOHNS MICHAEL M E GENUINE PARTS COMPANY 2999 CIRCLE 75 PKWY ATLANTA GA 30339 1 0 0 0

Dominic Caruso

Current Position:

Vice President, Finance and Chief Financial Officer, Johnson & Johnson, New Brunswick, United States

Employment History

General Manager of Diagnostic Division , Centocor , Inc., Malvern, United States

Chief Financial Officer , Centocor , Inc., Malvern, United States

Vice President, Finance , Centocor , Inc., Malvern, United States

Vice President of Finance , Ortho-McNeil Pharmaceutical , Inc., Raritan, United States

Vice President, Group Finance , Medical Devices and Diagnostics

Chief Financial Officer , J&J

Chief Financial Officer and Vice President for Fina nce , J&J

Vice President of Group Finance , J&J

Education

B.S., Business Administration , Drexel University

Web Reference

1. Johnson & Johnson - Investor Relations - Managem ent Team http://www.investor.jnj.com/governance/managementdetail.cfm?bioid=19177 Published on: 2012-02-29 Dominic J. Caruso Johnson & Johnson - Investor Relations - Management Team Careers Name: Dominic J. Caruso Biography: Dominic J. Caruso is Vice President, Finance and Chief Financial Officer of Johnson & Johnson. Mr. Caruso serves as a member of the Company's Executive Committee and has responsibility for financial and investor relations activities. He assumed his current position in January, 2007. Mr. Caruso joined the Corporation in October 1999 as Chief Financial Officer for Centocor, Inc., with the completion of the merger of Centocor and Johnson & Johnson. Prior to joining Johnson & Johnson, he had been with Centocor since 1985 with responsibilities for finance, information management, investor relations, procurement and facility services. He also served as general manager of Centocor's Diagnostic Division. Prior to joining Centocor, he had varied industry experiences with the audit and tax services firm KPMG. In 2001, Mr. Caruso was named Vice President of Finance for Ortho-McNeil Pharmaceutical and a member of its management board. He was named Vice President, Group Finance for Medical Devices & Diagnostics, and a member of the Medical Devices & Diagnostics Group Operating Committee in May, 2003. Mr. Caruso assumed responsibility for the Group Finance organization in December, 2005, the position he held until being named to his present position. Mr. Caruso graduated from Drexel University with a B.S. degree in business administration. Mr. Caruso resides in New Hope, Pennsylvania. He and his wife, Deborah, are the parents of three children and grandparents of four.

29


2. 2010 Annual Report - Johnson & Johnson http://www.investor.jnj.com/2010annualreport/board/index.html Published on: 2012-02-29 Dominic J. Caruso Vice President, Finance Chief Financial Officer

3. http://www.prnewswire.com/news-releases/johnson--johnson-to-participate-in-cowen-and-company-32nd-annual-health-care-conference-140702993.html Published on: 2012-02-28 Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session scheduled at 9:20 a.m. (Eastern Time).

4. http://www.fool.com/retirement/general/2012/01/31/5-star-stocks-poised-to-pop-johnson--johnson.aspx Published on: 2012-02-01 CFO Dominic Caruso

5. http://www.lincolndailynews.com/News/business012512_W.shtml Published on: 2012-01-26 Chief Financial Officer Dominic Caruso said he expects that will almost bounce back in 2012, when he expects earnings of $5.05 to $5.15 per share, excluding special items, and revenue of about $68 billion.

6. http://www.sec.gov/Archives/edgar/data/200406/0000200406-12-000008.txt Published on: 2012-01-19 0001385325 Caruso Dominic J JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 0 1 0 0 Chief Financial Officer

7. http://www.turnerinvestments.com/index.cfm/fuseaction/content.page/nodeID/8f394fdd%2D9370%2D4c38%2D8ab1%2D4ccfc877dd45/ Published on: 2011-11-21 As Dominic Caruso, chief financial officer at Johnson & Johnson, noted during an October conference call with security analysts, visits to the doctor were "declining dramatically.

8. http://www.lightninglabels.com/news/johnson-and-johnson-looks-to-reclaim-consumer-support- Published on: 2011-10-24 Dominic Caruso, Johnson & Johnson's chief financial officer, says the problem stems from quality. Several Johnson & Johnson products - ranging from children's Tylenol to Motrin - have been recalled over the past years, which has made consumers more conscious of other brands

9. http://www.manilatimes.net/business/jj-to-expand-services-center/ Published on: 2011-05-10 In a press conference on Tuesday, Dominic Caruso, J&J chief financial officer and vice president for finance, said the newly inaugurated $13.5-million Global Finance Services (GFS) Center in Parañaque City is serving the company's Asia-Pacific operations, with plans to handle financial transactions of subsidiaries outside the

30


region. Besides the Parañaque center, another GFS Center also serving Asia is located in China, but Caruso said the Philippine operations would be bigger. At present, about 100 employees man the GFS Center in Parañaque. Employment at the center is expected to reach 150 people by yearend. The four-story GFS Center has a capacity of almost 700 seats, which Caruso said the company aims to fill up "rapidly." Caruso said Philippine sales of consumer goods as well as pharmaceutical and medical devices under the J&J group in 2010 reached about $260 million, or 7.5 percent higher than in 2009. The local business however is a small portion of last year's global sales worth about $62 billion, he said.

10. http://www.drugstorenews.com/article/jj-mcneil-production-slow-down?ad=health-wellness Published on: 2011-04-20 And ... we will also embark on additional remediation efforts," said Dominic Caruso, J&J CFO and corporate VP finance. That slowdown in production will delay resumption of broad distribution of McNeil Consumer products until 2012 from a previous projection of the second half of 2011, Caruso said. "We expect to begin launching the products toward the back half of [2011], but the majority of the products will be launched in 2012," he said. Caruso suggested the lion's share of marketing that will herald McNeil's return to market will correspond to when most of McNeil's products are being brought back on line. Dominic Caruso

Michael Ullmann

Current Position:

Vice President, General Counsel, Johnson & Johnson, Skillman, United States Mergers and Acquisitions Attorney, Johnson & Johnson, Skillman, United States

Employment History

General Counsel , Company's Medical Devices

General Counsel , Diagnostics Group

Education

Cornell University , College of Arts & Sciences

law degree , Columbia University School of Law

Peter Fasolo

Current Position:

Board Member, HR Policy Association companies, Washington Dc, United States Worldwide Vice President Human Resources, Johnson & Johnson, New Brunswick, United States

Employment History

Vice President, Global Talent Management , Johnson & Johnson, New Brunswick, United States

Part of the Human Resources Function , Johnson & Johnson, New Brunswick, United States

Chief Talent Officer , Kohlberg Kravis Roberts & Co., Mount Kisco, United States

Senior Executive , Kohlberg Kravis Roberts & Co., Mount Kisco, United States

Senior Level Human Resources Executive Roles , Bristol-Myers Squibb Company, New York, United States

Head of Talent Management and Staffing , Bristol-Myers Squibb Company, New York, United States

Vice President, Human Resources , Worldwide

Worldwide Vice President Human Resources , Cordis Corporation, Miami, United States

Vice President , Global Talent Management

Education

Bachelor of Arts , Psychology , Providence College

Doctor of Philosophy , Organizational Psychology , The University of Delaware

31


Master of Arts degree , Industrial Psychology , Fairleigh Dickinson University

Web Reference

1. Johnson & Johnson - Investor Relations - Managem ent Team http://www.investor.jnj.com/textonly/governance/managementdetail.cfm?bioid=32340 Published on: 2012-02-29 Peter Fasolo Ph.D. | Text Only Johnson & Johnson - Investor Relations - Management Team Name: Peter Fasolo Ph.D. Peter M. Fasolo returned to Johnson & Johnson in September, 2010 as Worldwide Vice President Human Resources, responsible for the global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the Human Resources agenda for the Corporation. Peter is a member of the Executive Committee, Compensation Committee, and Chairs the Pension Committee for the Company. Prior to returning to Johnson & Johnson, Peter spent three years in private equity at Kohlberg Kravis Roberts & Co. (KKR) as Chief Talent Officer for the portfolio companies owned by the Firm. Peter was a member of KKR's Portfolio Management Committee, which oversees the strategic, operational and management issues of the various KKR companies. At KKR, Peter focused on Board composition, CEO and top executive assessment, selection, succession and long-term Executive compensation plans across the various industry groups. Peter's previous role at Johnson & Johnson was as Vice President, Global Talent Management where he was responsible for executive assessment and development for the Company and worked closely with the senior leadership to determine the talent needs of the business to execute the Corporate strategy. In 2004, Peter's first role at Johnson & Johnson was as Worldwide Vice President Human Resources for Cordis Corporation where he worked extensively on the merger and acquisition strategy for the Cordis cardiovascular business. Peter has more than 15 years experience in consulting, working directly in the healthcare and consumer industries, having spent 13 years with Bristol-Myers Squibb in senior level HR Executive roles in the Pharmaceutical, Medical Devices and Consumer segments. He has lived and worked in Paris, France and also had responsibility for Europe, Asia and Latin America in his career. Peter earned a Ph.D. in Organizational Behavior from the University of Delaware, an M.A. in Industrial Psychology from Fairleigh Dickinson University and a B.A. in Psychology from Providence College. He has lectured and written extensively in the area of workplace fairness, leadership, and workforce metrics. Peter has written a book chapter on workplace fairness and has published articles in the Academy of Management Journal and Journal of Applied Psychology. His current work was recently featured in Human Resources Executive (February, 2009).

2. Johnson & Johnson - Investor Relations - Managem ent Team http://www.investor.jnj.com/governance/management.cfm Published on: 2012-02-29 Peter Fasolo Ph.D.

3. 2010 Annual Report - Johnson & Johnson http://www.investor.jnj.com/2010annualreport/board/index.html Published on: 2012-02-29 Peter M. Fasolo Worldwide Vice President Human Resources

4. http://www.sec.gov/Archives/edgar/data/200406/0000200406-12-000012.txt Published on: 2012-01-19 0001509999 Fasolo Peter JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 0 1 0 0 VP, Worldwide Human Resources

Ian Davis

Current Position:

Non-Executive Director, BP p.l.c, London, United Kingdom Non-executive Director, Member of the Chairman's, the Audit and the Remuneration Committees, BP p.l.c, London, United Kingdom

Employment History

Independent Non-Executive Director , Teach

Independent Non-Executive Director , Johnson & Johnson, New Brunswick, United States

Worldwide Managing Director , McKinsey & Company, New York, United States

Chairman and Worldwide Managing Director , McKinsey & Company, New York, United States

32


Senior Partner and Director , McKinsey & Company, New York, United States

Education

bachelor's Degree , Philosophy and Economics , Oxford

Web Reference

1. Johnson & Johnson - Investor Relations - Board o f Directors http://www.investor.jnj.com/governance/biodetail.cfm?bioid=29273 Published on: 2012-02-29 Ian E. L. Davis Johnson & Johnson - Investor Relations - Board of Directors Careers Name: Ian E. L. Davis Biography: Mr. Davis was appointed to the Board of Directors in July 2010 and is a member of the Audit Committee and the Public Policy Advisory Committee. Mr. Davis is currently a Senior Advisor at Apax Partners, a private equity advisory firm. Mr. Davis retired from McKinsey & Company (management consulting) in 2010 as a Senior Partner, having served as Chairman and Worldwide Managing Director from 2003 until 2009. In his more than 30 years at McKinsey, he served as a consultant to a range of global organizations across the public, private and not-for-profit sectors. Prior to becoming Chairman and Worldwide Managing Director, he was Managing Partner of McKinsey's practice in the United Kingdom and Ireland. His experience includes oversight for McKinsey clients and services in Asia, Europe, the Middle East and Africa, as well as an expertise in the consumer products and retail industries. Mr. Davis is a Director of Teach for All, a global network of independent social enterprises working to expand educational opportunities in their nations a non-executive Director of global energy group, BP plc.; a non-executive member of the UK's Cabinet Office Board and serves on the International Advisory Committee of the King Abdullah Petroleum Studies and Research Centre. Having served as Chairman and Worldwide Managing Director of one of the world's leading management consulting firms, and as a consultant to a range of global organizations across the public, private and not-for-profit sectors, Mr. Davis brings considerable global experience, management insight and business knowledge to the Company's Board.

2. Johnson & Johnson - Investor Relations - Board of D irectors http://www.investor.jnj.com/textonly/governance/board.cfm Published on: 2012-02-29 Ian E. L. Davis Senior Advisor, Apax Partners; Former Chairman and Worldwide Managing Director, McKinsey & Company

3. Teach For All: About Us: Board http://www.teachforall.org/aboutus_board.html Published on: 2012-02-26 IAN DAVIS Managing Director Emeritus, McKinsey & Company Ian Davis is an independent non-executive director of BP plc, Johnson and Johnson Inc., and Teach for All, and is a senior adviser to Apax Partners LLP. He is also an independent non-executive member of the UK Cabinet Office board. He was a partner of McKinsey & Company for 31 years and served as Chairman and Worldwide Managing Director 2003 - 2009. He was educated at Oxford University and is married with two children.

4. Public Sector - Management articles from McKinsey Q uarterly http://www.mckinseyquarterly.com/Public_Sector/Management Published on: 2012-02-17 Ian Davis, managing director of McKinsey, talks about the public-sector productivity imperative.

5. http://www.trufflemedia.com/agmedia/blog/2012/01/19102/dairycast-update-january-19-2012-food-safety-isnt-interesting-until-it Published on: 2012-01-19 Audio: Do You Have Leadership Traits? - Ian Davis, retired Managing Director at McKinsey & Company, recently shared his top five leadership traits with Stanford's Graduate School of Business students. Ian has consulted with major international management leaders, seeing very good... and some not very good management teams. Ian Davis Nestlé

6. http://www.researchbank.co.uk/BP-Plc-Company-Profile.htm Published on: 2012-01-11 Ian Davis, Non executive director

33


7. http://www.sen.org.uk/news/big-society-bank-changes-name-and-appoints-chair-and-chief-executive Published on: 2011-12-29 Ian Davis (formerly McKinsey & Co)

8. http://www.letg.org.uk/news/?strUniqueID=5198313F-CB18-ADFD-ADF86AF56777B75A Published on: 2011-11-24 The Senior Partner of McKinsey, Ian Davis, will be sharing the insights he has gained from his career as a leader in McKinsey, and a consultant to leaders in business, on what works in developing leaders. Dame Sandra Dawson, a Non-Executive Director of the FSA and faculty member of the Judge Business School, "The Law Firm Partner as Leader", will share her views on the challenges facing leaders in an increasingly complex world.

9. The BP board | Who we are | BP http://www.bp.com/managedlistingsection.do?categoryId=9021626&contentId=7041219 Published on: 2011-09-18 Ian Davis Ian Davis Ian Davis Non-executive director Member of the chairman's, the audit, the nomination and the remuneration committees and chairman of the Gulf of Mexico committee Ian Davis's biography

10. Ian Davis| The board | BP http://www.bp.com/sectiongenericarticle.do?categoryId=9033139&contentId=7060705 Published on: 2011-04-21 Ian Davis Ian Davis Ian Davis Ian Davis, Non executive director Ian Davis joined the board as a non-executive director of BP on 2 April 2010. He is a member of the chairman's, the audit committee, the nomination and the remuneration and the chairman of the Gulf of Mexico committee. Mr Davis spent his early career at Bowater, moving to McKinsey & Company in 1979. He was managing partner of McKinseyâ??s practice in the UK and Ireland from 1996 to 2003. In 2003, he was appointed as chairman and worldwide managing director of McKinsey serving in this capacity until 2009. During his career with McKinsey, Mr Davis served as a consultant on a range of global organizations across the private, public and not-for-profit sectors. He retired as senior partner of McKinsey & Company in July 2010. Mr Davis is an independent non-executive director of Johnson & Johnson, hc., and a senior adviser to Apax Partners. He is also a non-executive member of the UK's cabinet office.

William Perez

Current Position:

Board Member, Johnson & Son Inc., Racine, United States President and Chief Executive Officer, Johnson & Son Inc., Racine, United States President and Chief Operating Officer, Johnson & Son Inc., Racine, United States

Employment History

President and Chief Executive Officer , Whirlpool Corporation, Benton Harbor, United States

President and Chief Executive Officer , Nike , Inc., Beaverton, United States

President and Chief Executive Officer , Wrigley Jr. Company, Chicago, United States

President and Chief Executive Officer , SC Johnson companies, Racine, United States

President and Chief Operating Officer , SC Johnson companies, Racine, United States

General Manager of the Operations , SC Johnson companies, Racine, United States

President and Chief Executive Officer , Wm

34


Education

graduate degree , International Management , Thunderbird School of Global Management

Bachelor of Arts degree , Government , Cornell University

graduate degree , International Management , Thunderbird School of International Management

Web Reference

1. Johnson & Johnson - Investor Relations - Board o f Directors http://www.investor.jnj.com/governance/biodetail.cfm?bioid=15648 Published on: 2012-02-29 William D. Perez Johnson & Johnson - Investor Relations - Board of Directors Careers Name: William D. Perez Title: Senior Advisor, Greenhill & Co., Inc. Retired President and Chief Executive Officer, Wm. Wrigley Jr. Company Biography: Mr. Perez was elected to the Board of Directors in 2007 and is Chairman of the Nominating & Corporate Governance Committee and a member of the Compensation & Benefits Committee. Mr. Perez is currently a Senior Advisor at Greenhill & Co., Inc., (investment banking). Mr. Perez served as President and Chief Executive Officer for the Wm. Wrigley Jr. Company (confectionary and chewing gum) from 2006 to 2008. Before joining Wrigley, Mr. Perez served as President and Chief Executive Officer of Nike, Inc. Previously, he spent 34 years with S.C. Johnson & Son, Inc., including eight years as its President and Chief Executive Officer. Mr. Perez is a Trustee for Cornell University and Northwestern Memorial Hospital. With his experience as CEO of several large, consumer-focused companies across a wide variety of industries, Mr. Perez contributes to the Company's Board significant organizational and operational management skills, combined with a wealth of experience in global, consumer-oriented businesses vital to a large public company in the consumer products space.

2. http://www.sec.gov/Archives/edgar/data/16732/0001209191-12-003308.txt Published on: 2012-01-11 0001184649 PEREZ WILLIAM D 1 CAMPBELL PLACE CAMDEN NJ 08103 1 0 0 0

3. http://www.sec.gov/Archives/edgar/data/200406/0000200406-11-000128.txt Published on: 2011-12-15 0001184649 PEREZ WILLIAM D JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 1 0 0 0

4. Campbell Soup Company - Governance - Board of Di rectors http://www.campbellsoupcompany.com/governance_board.asp Published on: 2011-11-10 William D. Perez Mr. Perez was President and Chief Executive Officer of the Wm. Wrigley Jr. Company from 2006 to 2008. Prior to joining Wrigley, he was President and Chief Executive Officer of Nike, Inc. from 2004 to 2006. Previously, he spent 34 years with S.C. Johnson & Son, Inc., including eight years as its President and Chief Executive Officer. Mr. Perez was elected to the Board of Directors in 2009.

5 http://www.sec.gov/Archives/edgar/data/106640/0001184649-11-000003.txt Published on: 2011-11-07 0001184649 PEREZ WILLIAM D 1320 N. STATE PARKWAY CHICAGO IL 60610 1 0 0 0

6. Whirlpool Corporation - Executive Committee http://www.whirlpoolcorp.com/leadership/executives/default.aspx Published on: 2011-09-05 William Perez

35


7. Greenhill & Co | A Unique Investment Banking Firm http://www.greenhill-co.com/index.php?option=com_peoplebook&Itemid=131&func=grShowProfile&profileid=10000322 Published on: 2011-03-22 William D. Perez Greenhill & Co | A Unique Investment Banking Firm William D. Perez Mr. Perez retired as President and Chief Executive Officer for the Wm. Wrigley Jr. Company in December of 2008. Before joining the Wrigley Company, he served as President and Chief Executive Officer of Nike, Inc. Previously, Mr. Perez spent 34 years with SC Johnson, including eight years as President and Chief Executive Officer. He serves on the Board of Directors for Campbell Soup Company, Johnson & Johnson, Whirlpool Corporation, Northwestern Memorial Hospital, the Boys and Girls Club of Chicago, and on the Board of Trustees for Cornell University. William D. Perez

LaVerne Council

Current Position:

Corporate Vice, President and Chief Information Officer, LaVerne Council

Employment History

Corporate Vice President and Chief Information Offi cer , Johnson & Johnson, New Brunswick, United States

Chief Information Officer Magazine , Johnson & Johnson, New Brunswick, United States

Vice President Chief Information Officer , JJ World Headqtrs US, New Brunswick, United States

Global Vice President for Information Technology, G lobal Business Solutions and Development Services , Dell Inc., Round Rock, United States

Vice President of Global Technology Development and Services , Dell Inc., Round Rock, United States

Global Leader for Infrastructure Engineering, Netwo rking , Dell Inc., Round Rock, United States

Partner , Ernst & Young LLP, New York, United States

Education

Illinois State University

Computer Science , Western Illinois University

Insured Profile Report – Management Liability Focus ......Johnson & Johnson 4/18/1982 $170.40...

Documents

Transcript of Insured Profile Report – Management Liability Focus ......Johnson & Johnson 4/18/1982 $170.40...